

Multi-Drug Rapid Test Panel (Urine) Package Insert

# Enalish

#### Instruction Sheet for testing of any combination of the following drugs: AMP/BAR/BZO/BUP/COC/THC/MTD/MET/MDMA/MOP/MQL/OPI/PCP/PPX/TCA/TRA/KET/ OXY/COT/EDDP/FYL/K2/ETG/K2+/ZOL/MCAT/MEP/UR-144

A rapid test for the simultaneous, qualitative detection of multiple drugs and drug metabolites in human urine .For healthcare professionals including professionals at point of care sites. Immunoassay for invitro diagnostic use only.

#### [INTENDED USE]

The Multi-Drug Rapid Test Panel is a rapid chromatographic immunoassay for the qualitative detection of multiple drugs and drug metabolites in urine at the following cut-off concentrations

Test	Calibrator	(ng/ml)
Amphetamine (AMP1,000)	d-Amphetamine	1,000
Amphetamine (AMP 500)	d-Amphetamine	500
Amphetamine (AMP 300)	d-Amphetamine	300
Barbiturates (BAR 300)	Secobarbital	300
Barbiturates (BAR 200)	Secobarbital	200
Benzodiazepines (BZO 500)	Oxazepam	500
Benzodiazepines (BZO 300)	Oxazepam	300
Benzodiazepines (BZO 200)	Oxazepam	200
Benzodiazepines (BZO 100)	Oxazepam	100
Buprenorphine (BUP)	Buprenorphine	10
Cocaine (COC 300)	Benzovlecgonine	300
Cocaine (COC150)	Benzovlecgonine	150
Cocaine (COC 100)	Benzovlecgonine	100
	2-ethylidene-1,5-dimethyl-	000
EDDP300	3,3-diphenylpyrrolidine	300
EDDP100	2-ethylidene-1,5-dimethyl-	100
Ethyl Glucuropide (ETG)	5,3-diphenyipyirolidine	500
Marijuana (THC150)		150
		50
Marijuana (THC 50)	11-101-29-THC-9 COOH	00
Marijuana (THC 25)	11-101-29-THC-9 COOH	20
Manjuana (THC 20)	11-101-29-1HC-9 COOH	20
Mathadara (MEP)		500
Methadone (MTD 300)	Methadone	300
Methadone (MTD 200)	Methadone	200
	d-Methamphetamine	1,000
Methamphetamine (MET 500)	d-Methamphetamine	500
Methamphetamine (MCAT)	d-methamphetamine	300
Methylanadioxymethomphotomino	Methcathinone	1,000
(MDMA 500)	d,I-Methylenedioxymethamphetamine	500
Methylenedioxymethamphetamine (MDMA 1,000)	d,I-Methylenedioxymethamphetamine	1,000
Methylenedioxymethamphetamine (MDMA 250)	d,I-Methylenedioxymethamphetamine	250
Methylenedioxymethamphetamine (MDMA 300)	d,I-Methylenedioxymethamphetamine	300
Morphine (MOP 300)	Morphine	300
Morphine (MOP 100)	Morphine	100
Methaqualone (MQL)	Methaqualone	300
Opiate (OPI 2,000)	Morphine	2,000
Opiate (OPI 1,000)	Morphine	1,000
Phencyclidine (PCP)	Phencyclidine	25
Propoxyphene (PPX)	Propoxyphene	300
Tricyclic Antidepressants (TCA)	Nortriptyline	1,000
Tramadol (TRA)	Tramadol	100
Ketamine (KET 1,000)	Ketamine	1,000
Ketamine (KET 500)	Ketamine	500
Ketamine (KET 300)	Ketamine	300
Oxycodone (OXY)	Oxycodone	100
Cotinine (COT200)	Cotinine	200
Cotinine (COT100)	Cotinine	100
Fentanyl (FYL20)	Norfentanyl	20

Fentanyl (FYL10)	Norfentanyl	10
Synthetic Marijuana (K2-50)	JWH-073,JWH-018	50
Synthetic Marijuana (K2-30)	JWH-073,JWH-018	30
Synthetic Marijuana (K2+)	AB-PINACA pentanoic acid metabolite	10
UR-144	UR-144 5-Pentanoic acid metabolite	25
Zolpidem (ZOL)	Zolpidem	50

Configurations of the Multi-Drug Rapid Test Panel come with any combination of the above listed drug analytes. This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

### (SUMMARY)

The Multi-Drug Rapid Test Panel is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes monoclonal antibodies to selectively detect elevated levels of specific drugs in urine.

#### Amphetamine (AMP 1.000)

Amphetamine is a Schedule II controlled substance available by prescription (Dexedrine®) and is also available on the illicit market. Amphetamines are a class of potent sympathomimetic agents with therapeutic applications. They are chemically related to the human body's natural catecholamines: epinephrine and norepinephrine. Acute higher doses lead to enhanced stimulation of the central nervous system (CNS) and induce euphoria, alertness, reduced appetite, and a sense of increased energy and power. Cardiovascular responses to amphetamines include increased blood pressure and cardiac arrhythmias. More acute responses produce anxiety, paranoia, hallucinations, and psychotic behavior. The effects of Amphetamines generally last 2-4 hours following use and the drug has a half-life of 4-24 hours in the body. About 30% of amphetamines are excreted in the urine in unchanged form, with the remainder as hydroxylated and deaminated derivatives.

The Multi-Drug Rapid Test Panel vields a positive result when the concentration of amphetamines in urine exceeds 1,000ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).

# Amphetamine (AMP 500)

The Multi-Drug Rapid Test Panel yields a positive result when amphetamines in urine exceed 500ng/mL. See Amphetamine (AMP 1,000) for the summary.

# Amphetamine (AMP 300)

The Multi-Drug Rapid Test Panel yields a positive result when amphetamines in urine exceed 300ng/mL. See Amphetamine (AMP 1,000) for the summary.

# Barbiturates (BAR 300)

Barbiturates are CNS depressants. They are used therapeutically as sedatives, hypnotics, and anticonvulsants barbiturates are almost always taken orally as capsules or tablets. The effects resemble those of intoxication with alcohol. Chronic use of barbiturates leads to tolerance and physical dependence.

Short-acting barbiturates taken at 400 mg/day for 2-3 months can produce a clinically significant degree of physical dependence. Withdrawal symptoms experienced during periods of drug abstinence can be severe enough to cause death.

Only a small amount (less than 5%) of most barbiturates are excreted unaltered in the urine. The approximate detection time limits for barbiturates are: Short ac

Short acting (e.g. Secobarbital)	100 mg PO (oral)	4.5 days
Long acting (e.g. Phenobarbital)	400 mg PO (oral)	7 days <sup>2</sup>
e Multi-Drug Rapid Test Panel vield	s a positive result when the	concentrat

The Multi-I ation of secobarbital in urine exceeds 300ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for Barbiturate positive specimens.

# Barbiturates (BAR 200)

The Multi-Drug Rapid Test Panel yields a positive result when secobarbital in urine exceed 200ng/mL. See Barbiturates (BAR 300) for the summary.

# Benzodiazepines (BZO 500)

Benzodiazepines are medications that are frequently prescribed for the symptomatic treatment of anxiety and sleep disorders. They produce their effects via specific receptors involving a neurochemical called gamma aminobutyric acid (GABA). Because they are safer and more effective, benzodiazepines have replaced barbiturates in the treatment of both anxiety and insomnia. Benzodiazepines are also used as sedatives before some surgical and medical procedures, and for the treatment of seizure disorders and alcohol withdrawal.

Risk of physical dependence increases if benzodiazepines are taken regularly (e.g., daily) for more than a few months, especially at higher than normal doses. Stopping abruptly can bring on such symptoms as trouble sleeping, gastrointestinal upset, feeling unwell, loss of appetite, sweating, trembling, weakness, anxiety and changes in perception.

Only trace amounts (less than 1%) of most benzodiazepines are excreted unaltered in the urine; most of the concentration in urine is conjugated drug. The detection period for benzodiazepines in urine is 3-7 days.

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of oxazepam in urine exceeds 500ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for benzodiazepine positive specimens.

#### Benzodiazepines (BZO 300)

The Multi-Drug Rapid Test Panel yields a positive result when oxazepam in urine exceed 300ng/mL. See Benzodiazepines (BZO 500) for the summary.

#### Benzodiazepines (BZO 200)

The Multi-Drug Rapid Test Panel yields a positive result when oxazepam in urine exceed 200ng/mL. See Benzodiazepines (BZO 500) for the summary.

Benzodiazepines (BZO 100)

The Multi-Drug Rapid Test Panel yields a positive result when oxazepam in urine exceed

100ng/mL. See Benzodiazepines (BZO 500) for the summary. Buprenorphine (BUP)

Buprenorphine is a potent analgesic often used in the treatment of opioid addiction. The drug is sold under the trade names Subutex<sup>™</sup>. Buprenex<sup>™</sup>. Temoesic<sup>™</sup> and Suboxone<sup>™</sup>. which contain Buprenorphine HCl alone or in combination with Naloxone HCl. Therapeutically, Buprenorphine is used as a substitution treatment for opioid addicts. Substitution treatment is a form of medical care offered to opiate addicts (primarily heroin addicts) based on a similar or identical substance to the drug normally used. In substitution therapy, Buprenorphine is as effective as Methadone but demonstrates a lower level of physical dependence. Concentrations of free Buprenorphine and Norbuprenorphine in urine may be less than 1 ng/ml after therapeutic administration, but can range up to 20 ng/ml in abuse situations. The plasma half-life of Buprenorphine is 2-4 hours.<sup>7</sup>While complete elimination of a single dose of the drug can take as long as 6 days, the window of detection for the parent drug in urine is thought to be approximately 3 days.

Substantial abuse of Buprenorphine has also been reported in many countries where various forms of the drug are available. The drug has been diverted from legitimate channels through theft, doctor shopping, and fraudulent prescriptions, and been abused via intravenous, sublingual, intranasal and inhalation routes.

The Multi-Drug Rapid Test Panel yields a positive result when the Buprenorphine in urine exceeds 10ng/mL

# Cocaine(COC 300)

Cocaine is a potent central nervous system stimulant and a local anesthetic. Initially, it brings about extreme energy and restlessness while gradually resulting in tremors, over-sensitivity and spasms. In large amounts, cocaine causes fever, unresponsiveness, difficulty in breathing and unconsciousness.

Cocaine is often self-administered by nasal inhalation, intravenous injection and free-base smoking. It is excreted in the urine in a short time primarily as benzoylecgonine. Benzoylecgonine, a major metabolite of cocaine, has a longer biological half-life (5-8 hours) than cocaine (0.5-1.5 hours), and can generally be detected for 24-48 hours after cocaine exposure.

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of benzoylecgonine in urine exceeds 300ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA USA)

# Cocaine (COC 150)

The Multi-Drug Rapid Test Cassette yields a positive result when the concentration of benzoylecgonine in urine exceeds 150ng/mL. See Cocaine (COC 300) for the summary. Cocaine (COC 100)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of benzoylecgonine in urine exceeds 100ng/mL. See Cocaine (COC 300) for the summary. Marijuana (THC150)

THC (Δ9-tetrahydrocannabinol) is the primary active ingredient in cannabis (marijuana). When smoked or orally administered, THC produces euphoric effects. Users have impaired short-term memory and slowed learning. They may also experience transient episodes of confusion and anxiety. Long-term, relatively heavy use may be associated with behavioral disorders. The peak effect of marijuana administered by smoking occurs in 20-30 minutes and the duration is 90-120 minutes after one cigarette. Elevated levels of urinary metabolites are found within hours of exposure and remain detectable for 3-10 days after smoking. The main metabolite excreted in the urine is 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of THC-COOH in urine exceeds 150ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, LISA)

# Marijuana (THC50)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of THC-COOH in urine exceeds 50ng/mL. See Marijuana (THC150) for the summary Marijuana (THC25)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of THC-COOH in urine exceeds 25ng/mL. See Marijuana (THC150) for the summary.

# Marijuana (THC20)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of THC-COOH in urine exceeds 20 ng/mL. See Marijuana (THC150) for the summary. Methadone (MTD300)

Methadone is a narcotic analgesic prescribed for the management of moderate to severe pain and for the treatment of opiate dependence (heroin, Vicodin, Percocet, morphine). The pharmacology of oral methadone is very different from IV methadone. Oral methadone is partially stored in the liver for later use. IV methadone acts more like heroin. In most states you must go to a pain clinic or a methadone maintenance clinic to be prescribed methadone.

Methadone is a long acting pain reliever producing effects that last from twelve to forty-eight hours. Ideally, methadone frees the client from the pressures of obtaining illegal heroin, from the dangers of injection, and from the emotional roller coaster that most opiates produce. Methadone, if taken for long periods and at large doses, can lead to a very long withdrawal period. The withdrawals from methadone are more prolonged and troublesome than those provoked by heroin cessation, yet the substitution and phased removal of methadone is an acceptable method of detoxification for patients and therapists.

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of methadone in urine exceeds 300ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for methadone positive specimens

#### Methadone (MTD200)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of methadone in urine exceeds 200ng/mL. See Methadone (MTD300)for the summary.

### Methamphetamine (MET 1,000)

Methamphetamine is an addictive stimulant drug that strongly activates certain systems in the

brain. Methamphetamine is closely related chemically to Amphetamine, but the central nervous system effects of Methamphetamine are greater. Methamphetamine is made in illegal laboratories and has a high potential for abuse and dependence. The drug can be taken orally, injected, or inhaled. Acute higher doses lead to enhanced stimulation of the central nervous system and induce euphoria, alertness, reduced appetite, and a sense of increased energy and power. Cardiovascular responses to Methamphetamine include increased blood pressure and cardiac arrhythmias. More acute responses produce anxiety, paranoia, hallucinations, psychotic behavior, and eventually, depression and exhaustion.

The effects of Methamphetamine generally last 2-4 hours and the drug have a half-life of 9-24 hours in the body. Methamphetamine is excreted in the urine primarily as Amphetamine, and oxidized and deaminated derivatives. However, 10-20% of Methamphetamine is excreted unchanged. Thus, the presence of the parent compound in the urine indicates Methamphetamine use. Methamphetamine is generally detectable in the urine for 3-5 days, depending on urine pH level.

The Multi-Drug Rapid Test Panel is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Methamphetamine in urine. The Multi-Drug Rapid Test Panel yields a positive result when the Methamphetamine in urine exceeds 1,000ng/mL

## Methamphetamine (MFT 500)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Methamphetamine in urine exceeds 500ng/mL. See Methamphetamine (MET1,000) for the summary

#### Methamphetamine (MET 300)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Methamphetamine in urine exceeds 300ng/mL. See Methamphetamine (MET1.000) for the summarv

#### Methylenedioxymethamphetamine (MDMA500)

Methylenedioxymethamphetamine (ecstasy) is a designer drug first synthesized in 1914 by a German drug company for the treatment of obesity.<sup>5</sup> Those who take the drug frequently report adverse effects, such as increased muscle tension and sweating. MDMA is not clearly a stimulant, although it has, in common with amphetamine drugs, a capacity to increase blood pressure and heart rate. MDMA does produce some perceptual changes in the form of increased sensitivity to light, difficulty in focusing, and blurred vision in some users. Its mechanism of action is thought to be via release of the neurotransmitter serotonin. MDMA may also release dopamine, although the general opinion is that this is a secondary effect of the drug (Nichols and Oberlender, 1990). The most pervasive effect of MDMA, occurring in virtually all people who took a reasonable dose of the drug, was to produce a clenching of the jaws.

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Methylenedioxymethamphetamine in urine exceeds 500ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for Methylenedioxymethamphetamine positive specimens.

#### Methylenedioxymethamphetamine (MDMA1,000)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of methylenedioxymethamphetamine in urine exceeds 1,000ng/mL. See methylenedioxymethamphetamine (MDMA500) for the summary.

# Methylenedioxymethamphetamine (MDMA250)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of methylenedioxymethamphetamine in urine exceeds 250ng/mL. See methylenedioxymethamphetamine (MDMA500) for the summary.

#### Methylenedioxymethamphetamine (MDMA300)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of in urine exceeds methylenedioxymethamphetamine 300na/mL. methylenedioxymethamphetamine (MDMA500) for the summary.

#### Morphine (MOP 300)

Opiate refers to any drug that is derived from the opium poppy, including the natural products, morphine and codeine, and the semi-synthetic drugs such as heroin. Opioid is more general, referring to any drug that acts on the opioid receptor.

Opioid analgesics comprise a large group of substances which control pain by depressing the CNS. Large doses of morphine can produce higher tolerance levels, physiological dependency in users, and may lead to substance abuse. Morphine is excreted unmetabolized, and is also the major metabolic product of codeine and heroin. Morphine is detectable in the urine for several days after an opiate dose.

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of morphine in urine exceeds 300na/mL.

# Morphine (MOP 100)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of morphine in urine exceeds 100ng/mL. See Morphine (MOP300) for the summary.

## Morphine/Opiate (OPI 2.000)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of morphine in urine exceeds 2,000ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).<sup>1</sup> See morphine (MOP 300) for summary.

# Morphine/Opiate (OPI 1,000)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of morphine in urine exceeds 1,000ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).<sup>1</sup> See morphine (MOP 300) for summary.

#### Methagualone (MQL)

Methagualone (Quaalude, Sopor) is a guinazoline derivative that was first synthesized in 1951 and found clinically effective as a sedative and hypnotic in 1956.<sup>10</sup>It soon gained popularity as a drug of abuse and in 1984 was removed from the US market due to extensive misuse. It is occasionally encountered in illicit form, and is also available in European countries in combination with diphenhydramine (Mandrax). Methaqualone is extensively metabolized in vivo principally by hydroxylation at every possible position on the molecule. At least 12 metabolites have been identified in the urine.

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Methaqualone in urine exceeds 300ng/mL.

#### Phencyclidine (PCP)

Phencyclidine, also known as PCP or Angel Dust, is a hallucinogen that was first marketed as a surgical anesthetic in the 1950's. It was removed from the market because patients receiving it became delirious and experienced hallucinations.

PCP is used in powder, capsule, and tablet form. The powder is either snorted or smoked after mixing it with marijuana or vegetable matter. PCP is most commonly administered by inhalation but can be used intravenously, intra-nasally, and orally. After low doses, the user thinks and acts swiftly and experiences mood swings from euphoria to depression. Self-injurious behavior is one of the devastating effects of PCP.

PCP can be found in urine within 4 to 6 hours after use and will remain in urine for 7 to 14 days, depending on factors such as metabolic rate, user's age, weight, activity, and diet.6 PCP is excreted in the urine as an unchanged drug (4% to 19%) and conjugated metabolites (25% to 30%).

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of phencyclidine in urine exceeds 25 ng/mL. This is the suggested screening cut-off for positive specimens set by the Substance Abuse and Mental Health Services Administration (SAMHSA, USA).

#### Propoxyphene (PPX)

Propoxyphene (PPX) is a narcotic analgesic compound bearing structural similarity to methadone. As an analgesic, propoxyphene can be from 50-75% as potent as oral codeine. Darvocet<sup>™</sup>, one of the most common brand names for the drug, contains 50-100 mg of propoxyphene napsylate and 325-650 mg of acetaminophen. Peak plasma concentrations of propoxyphene are achieved from 1 to 2 hours post dose. In the case of overdose, propoxyphene blood concentrations can reach significantly higher levels.

In humans, propoxyphene is metabolized by N-demethylation to yield norpropoxyphene. Norpropoxyphene has a longer half-life (30 to 36 hours) than parent propoxyphene (6 to 12 hours).The accumulation of norpropoxyphene seen with repeated doses may be largely responsible for resultant toxicity.

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Propoxyphene or Norpropoxyphene in urine exceeds 300 ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for propoxyphene positive specimens.

#### Tricyclic Antidepressants (TCA)

TCA (Tricyclic Antidepressants) are commonly used for the treatment of depressive disorders. TCA overdoses can result in profound CNS depression, cardiotoxicity and anticholinergic effects. TCA overdose is the most common cause of death from prescription drugs. TCAs are taken orally or sometimes by injection. TCAs are metabolized in the liver. Both TCAs and their metabolites are excreted in urine mostly in the form of metabolites for up to ten days.

The Multi-Drug Rapid Test Panelyields a positive result when the concentration of nortriptyline in urine exceeds 1,000 ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for tricyclic antidepressant positive specimens.

#### Tramadol (TRA)

Tramadol(TRA) is a quasi-narcotic analgesic used in the treatment of moderate to severe pain. It is a synthetic analog of codeine, but has a low binding affinity to the mu-opioid receptors. Large doses of tramadol can develop tolerance and physiological dependency and lead to its abuse. Tramadol is extensively metabolized after oral administration. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% is excreted as metabolites. The major pathways appear to be N- and O- demethylation, glucoronidation or sulfation in the liver

The Multi-Drug Rapid Test Panel is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Tramadol in urine. The Multi-Drug Rapid Test Panel yields a positive result when Tramadol in urine exceed 100ng/mL.

## Ketamine(KET1.000)

Ketamine is a dissociative anesthetic developed in 1963 to replace PCP (Phencyclidine). While Ketamine is still used in human anesthesia and veterinary medicine, it is becoming increasingly abused as a street drug. Ketamine is molecularly similar to PCP and thus creates similar effects including numbness, loss of coordination, sense of invulnerability, muscle rigidity, aggressive / violent behavior, slurred or blocked speech, exaggerated sense of strength, and a blank stare. There is depression of respiratory function but not of the central nervous system and cardiovascular function is maintained. The effects of Ketamine generally last 4-6 hours following use. Ketamine is excreted in the urine as unchanged drug (2.3%) and metabolites (96.8%)

The Multi-Drug Rapid Test Panel is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Ketamine in urine. The Multi-Drug Rapid Test Panel yields a positive result when Ketamine in urine exceeds 1.000ng/mL.

# Ketamine (KET500)

The Multi-Drug Rapid Test Panel vields a positive result when the concentration of Ketamine in urine exceeds 500ng/mL. See Ketamine(KET1,000) for the summary.

#### Ketamine (KET300)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Ketamine in urine exceeds 300ng/mL. See Ketamine (KET1,000) for the summary.

#### Oxycodone (OXY)

Oxycodone is a semi-synthetic opioid with a structural similarity to codeine. The drug is manufactured by modifying the baine, an alkaloid found in the opium poppy. Oxycodone, like all opiate agonists, provides pain relief by acting on opioid receptors in the spinal cord, brain, and possibly directly in the affected tissues. Oxycodone is prescribed for the relief of moderate to high pain under the well-known pharmaceutical trade names of OxvContin®. Tvlox®. Percodan® and Percocet®. While Tylox®, Percodan® and Percocet® contain only small doses of oxycodone hydrochloride combined with other analgesics such as acetaminophen or

aspirin, OxyContin consists solely of oxycodone hydrochloride in a time-release form. Oxycodone is known to metabolize by demethylation into oxymorphone and noroxycodone. In a 24-hour urine, 33-61% of a single, 5 mg oral dose is excreted with the primary constituents being unchanged drug (13-19%), conjugated drug (7-29%) and conjugated oxymorphone (13-14%). The window of detection for Oxycodone in urine is expected to be similar to that of other opioids such as morphine.

The Multi-Drug Rapid Test Panel is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Oxycodone in urine. The Multi-Drug Rapid Test Panel yields a positive result when Oxycodone in urine exceeds 100ng/mL.

#### Cotinine (COT 200)

Cotinine is the first-stage metabolite of nicotine, a toxic alkaloid that produces stimulation of the autonomic ganglia and central nervous system when in humans. Nicotine is a drug to which virtually every member of a tobacco-smoking society is exposed whether through direct contact or second-hand inhalation. In addition to tobacco, nicotine is also commercially available as the active ingredient in smoking replacement therapies such as nicotine gum, transdermal patches and nasal sprays.

In a 24-hour urine, approximately 5% of a nicotine dose is excreted as unchanged drug with 10% as cotinine and 35% as hydroxycotinine; the concentrations of other metabolites are believed to account for less than 5%. <sup>10</sup>While cotinine is thought to be an inactive metabolite, it's elimination profile is more stable than that of nicotine which is largely urine pH dependent. As a result cotinine is considered a good biological marker for determining nicotine use. The plasma half-life of nicotine is approximately 60 minutes following inhalation or parenteral administration.<sup>11</sup>Nicotine and cotinine are rapidly eliminated by the kidney; the window of detection for cotinine in urine at a cutoff level of 200ng/mL is expected to be up to 2-3 days after nicotine use.

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Cotinine in urine exceeds 200ng/ml

#### Cotinine (COT 100)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Cotinine in urine exceeds 100ng/mL. See Cotinine(COT200) for the summary

# 2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP 300)

Methadone is an unusual drug in that its primary urinary metabolites (EDDP and EMDP) are cyclic in structure, making them very difficult to detect using immunoassays targeted to the native compound.<sup>10</sup>Exacerbating this problem, there is a subsection of the population classified as "extensive metabolizers" of methadone. In these individuals, a urine specimen may not contain enough parent methadone to yield a positive drug screen even if the individual is in compliance with their methadone maintenance. EDDP represents a better urine marker for methadone maintenance than unmetabolized methadone.

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of EDDP in urine exceeds 300ng/mL. At present, the Substance Abuse and Mental Health Services Administration (SAMHSA) does not have a recommended screening cut-off for EDDP positive specimens.

# 2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP 100)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of EDDP in urine exceeds 100ng/mL. See EDDP 300 for the summary. Fentanyl (FYL20)

Fentanyl, belongs to powerful narcotics analgesics, and is a µ special opiates receptor stimulant. Fentanyl is one of the varieties that been listed in management of United Nations "Single Convention of narcotic drug in 1961". Among the opiates agents that under international control, fentanyl is one of the most commonly used to cure moderate to severe pain<sup>1</sup>. After continuous injection of fentanyl, the sufferer will have the performance of protracted opioid abstinence syndrome, such as ataxia and irritability etc<sup>2,3</sup>, which presents the addiction after taking fentanyl in a long time. Compared with drug addicts of amphetamine, drug addicts who take fentanyl mainly have got the possibility of higher infection rate of HIV. more dangerous injection behavior and more lifelong medication overdose

The FYL Rapid Test Panel (Urine) is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of norfentanyl in urine. The FYL Rapid Test Panel (Urine) yields a positive result when norfentanyl in urine exceeds 20ng/mL.

# Fentanyl (FYI 10)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Norfentanyl in urine exceeds 10ng/mL. See FYL20 for the summary.

## Synthetic Marijuana (K2-50)

Synthetic Marijuana or K2 a psychoactive herbal and chemical product that when consumed, mimics the effects of Marijuana. It is best known by the brandnames K2 and Spice, both of which have largely become genericized trade marks used to refer to any synthetic Marijuana product. The studies suggest that synthetic marijuana intoxication is associated with acute psychosis, worsening of previously stable psychotic disorders, and also may have the ability to trigger achronic (long-term) psychotic disorder among vulnerable individuals such as those with a family history of mental illness.

Elevated levels of urinary metabolites are found within hours of exposure and remain detectable for 72 hours after smoking (depending on usage/dosage). As of March 1, 2011, five cannabinoids, JWH -018, JWH- 073, CP- 47, JWH- 200and cannabicyclo hexanol are now illegal in the US because these substances have the potential to be extremely harmful and, therefore, pose an imminenthazard to the public safety.

The Multi-Drug Rapid Test Panel yields a positive result when the synthetic marijuana metabolite in urine exceeds 50ng/mL

#### Synthetic Marijuana (K2-30)

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of the synthetic marijuana metabolite in urine exceeds 30ng/mL. See K2-50 for the summary.

# Ethyl Glucuronide (ETG 500)

Ethyl glucuronide (ETG) is a metabolite of ethyl alcohol which is formed in the body by glucuronidation following exposure to ethanol, usually from drinking alcoholic beverages. After Alcohol is absorbed by the body, 90-95% Alcohol is oxidized with the help of emzymes. Only 0.5%-1.5% Alcohol integrates with glucose into Ethyl Glucuronide. ETG remains in urine longer period than Alcohol. When low Alcohol volume is drunk (such as 0.1g/kg), ETG detection window varies from 13 - 20hours after drinking. However, maximum ETG detection window can be 80 hours for high Alcohol volume drinking.

The Multi-Drug Rapid Test Panel yields a positive result when the Ethyl Glucuronide in urine exceeds 500ng/mL.

# Synthetic Marijuana (K2+)

Synthetic cannabinoids are designer drugs that are structurally different from THC (the active component of cannabis) but act in similar ways to affect the cannabinoid receptor system in the brain. Over the past few years, this class of designer drugs has mainstreamed to become globally popular and increasingly problematic. Synthetic cannabinoids fall into seven major structural groups:

- 1 .Naphthoylindoles (e.g. JWH-018, JWH-073)
- 2. Naphthylmethylindoles (JWH-175, JWH-184, JWH-185, JWH-199)
- 3 .Naphthoylpyrroles (JWH-145, JWH-146, JWH-147, etc)
- 4. Naphthylmethylindenes (JWH-176)
- 5. Phenylacetylindoles (JWH-250, JWH-251, JWH-302)
- 6. Cyclohexylphenols (e.g. CP 47,497)

7. Dibenzopyrans (classic cannabinoid structure such as. HU-210 and HU-211)

New structural group: Aminoalkylindazoles (AB-PINACA, ÅB-FUBINACA, ÅB-CHMINACA, etc)In their original, chemical state, synthetic cannabinoids are liquid. The drugs are usually sold combined with dried herbs that emulate marijuana and are intended for smoking although powdered versions are also available. As laws are written to control these drugs with each new synthetic cannabinoid class as they are introduced to the market, the older versions (JWH-018,JWH-073) are seen less frequently than years past. The current trend shows the aminoalkylindazole based drugs such as AB-PINACA, AB-FUBINACA and AB-CHMINACA. The Synthetic Marijuana K2+(AB-Pinaca) Rapid Test Panel (Urine) is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of Synthetic Marijuana(K2+) metabolite in human urine. The Synthetic Marijuana K2+(AB-Pinaca) Rapid Test Panel (Urine) yields a positive result when the AB-PINACA pentanoic acid metabolite in urine exceeds10ng/mL.

#### Zolpidem (ZOL50)

Zolpidem is a non-benzodiazepine hypnotic sold under the trade names Ambien®, Stilnox® and Edluar® for the treatment of insomnia. Zolpidem has not adequately demonstrated effectiveness in maintaining sleep, unless delivered in a controlled-release (CR) form. However, it is effective in initiating sleep.It works quickly, usually within 15 minutes, and has a short half-life of 2-3 hours. Because the characteristic of quick effect, low side effect, etc,

Zolpidem has the trend of gradually replacing the barbiturates and benzodiazepine sleeping pills. The result of its widely used and easily obtained, the criminal cases showed a trend of rising.Zolpidem Phenyl-4-carboxylic acid is the major urinary metabolite of zolpidem, accounting for 51% of an administered dose. Literature references indicate the metabolite can be found in urine after ingesting a single therapeutic dose of zolpidem, for 2-3 days. Only 1% Zolpidem was extracted with original version by urine.<sup>12,13</sup>

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Zolpidem Phenyl-4-carboxylic acid in urine exceeds 50ng/mL.

# Methcathinone (MCAT 1000)

Methcathinone, a methyl derivative of cathinone, is an illicit drug also known as ephedrone. It is a stimulant found in the "khat" plant, Catha edulis, which can easily be synthesized from pseudoephedrine. It is used as a recreational drug due to its potent stimulant and euphoric effects and is considered to be addictive, with both physical and psychological withdrawal occurring if its use is discontinued after prolonged or high-dosage administration. It is usually snorted, but can be smoked, injected, or taken orally. Effects of this drug typically last from 4 to 6 hours.

Methcathinone is listed as a Schedule I controlled substance by the Convention on Psychotropic Substances and the United States' Controlled Substances Act, and as such it is not considered to be safe or effective in the treatment, diagnosis, prevention, or cure of any disease, and has no approved medical use. Possession and distribution of methcathinone for the purpose of human consumption is illegal under any/all circumstances in the United States and is either illegal or highly regulated in most jurisdictions world-wide.

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Methcathinone in urine exceeds 1000ng/mL.

#### Mephedrone (MEP 500)

Mephedrone, also known as 4-methylmethcathinone(4-MMC) or 4-methylephedrone, is a synthetic stimulant drug of the amphetamine and cathinone classes. Slang names include bath salts, drone, M-CAT, White Magic and meow meow. It is chemically similar to the cathinone compounds found in the khat plant of eastern Africa.

Mephedrone has been used as a recreational drug in Europe and elsewhere in the world since 2007. It comes in the form of tablets or a powder, which users can swallow, snort or inject, producing similar effects to MDMA, amphetamines and cocaine. In addition to its stimulant effects, mephedrone produces side effects, of which teeth grinding are the most common. A number of metabolites are possible, however the n-demethyl metabolite of Mephedrone will be 4-Methylcathinone. This metabolite appears to be nearly inactive as a Monoamine Oxydase Inhibitor. On further metabolism of this metabolite one of the possible metabolites is 4-Methylnorephedrine, caused by the reduction of the Keto.

The Multi-Drug Rapid Test Panel yields a positive result when the concentration of Mephedrone in urine exceeds 500ng/mL.

# UR-144

UR-144 5-Pentanoic acid metabolite, a primary urinary metabolite of UR-144, a synthetic cannabinoid found in many blends of the herbal mixture Spice also known as K2, Genie, or Demon, which has been detected in many 'legal highs', seized from the global drug market since the beginning of 2012. (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) is a synthetic cannabinoid receptor agonist (SCRA) that binds to and activates CB1 and CB2 receptors and the currently available data also suggest that UR-144 shows selectivity towards the CB2 receptor. Although there is an increasing indication that some SCRAs have been associated with dependence producing features, studies related to UR-144 specifically are not available. Abuse potential: Clinical studies in humans could not be identified. Pharmacological investigations (in vitro and in vivo) confirmed that UR-144 shares similarities with Δ9-THC and other cannabinoid receptor agonists in its mechanisms of action, which was in alignment with the documented history of its use over several years since it emerged as a 'research chemical' around 2012. Most commonly, this substance is encountered in the form of smokable 'herbal mixtures' although other forms have also been identified

The UR-144 Rapid Test is a rapid urine screening test that can be performed without the use of an instrument. The test utilizes a monoclonal antibody to selectively detect elevated levels of UR-144 S-Pentanoic acid metabolite in urine.

The Multi-Drug Rapid Test Panel yields a positive result when UR-144 5-Pentanoic acid metabolite in urine reaches 25 ng/mL.

#### (PRINCIPLE)

During testing, a urine specimen migrates upward by capillary action. A drug, if present in the urine specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test region of the specific drug strip. The presence of drug above the cut-off concentration will saturate all the binding sites of the antibody. Therefore, the colored line will not form in the test region.

A drug-positive urine specimen will not generate a colored line in the specific test region of the strip because of drug competition, while a drug-negative urine specimen will generate a line in the test region because of the absence of drug competition.

To serve as a procedural control, a colored line will always appear at the control region, indicating that proper volume of specimen has been added and membrane wicking has occurred.

# [REAGENTS]

Each test line contains anti-drug mouse monoclonal antibody and corresponding drug-protein conjugates. The control line contains goat anti-rabbit IgG polyclonal antibodies and rabbit IgG. **[PRECAUTIONS]** 

- · For healthcare professionals including professionals at point of care sites.
- Immunoassay for invitro diagnostic use only. The test panel should remain in the sealed pouch until use.
- All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent.

The used test panel should be discarded according to federal, state and local regulations.
 [STORAGE AND STABILITY]

Store as packaged in the sealed pouch at 2-30°C. The test is stable through the expiration date printed on the sealed pouch. The test panels must remain in the sealed pouch until use. **DO NOT FREEZE**. Do not use beyond the expiration date. **[SPECIMEN COLLECTION AND PREPARATION]** 

## Urine Assay

The urine specimen should be collected in a clean and dry container. Urine collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be centrifuged, filtered, or allowed to settle to obtain a clear specimen for testing.

# Specimen Storage

Urine specimens may be stored at 2-8°C for up to 48 hours prior to testing. For prolonged storage, specimens may be frozen and stored below -20°C. Frozen specimens should be thawed and mixed well before testing. [MATERIALS]

#### Materials Provided

- Test Panels
   Package insert
   Materials Required But Not Provided
- Specimen collection container
- [DIRECTIONS FOR USE]

# Allow the test panel, urine specimen, and/or controls to equilibrate to room temperature (15-30°C) prior to testing.

time

- Bring the pouch to room temperature before opening it. Remove the test panel from the sealed pouch and use it within one hour.
- 2. Remove the cap.
- 3. With the arrow pointing toward the urine specimen, immerse the test panel vertically in the urine specimen for at least 10 to 15 seconds. Immerse the strip to at least the level of the wavy lines, but not above the arrow on the test panel.
- 4. Replace the cap and place the test panel on a non-absorbent flat surface.
- 5. Start the timer and wait for the colored line(s) to appear.
- 6. The result should be read at 5 minutes. Do not interpret the result after 10 minutes.



#### [INTERPRETATION OF RESULTS]

# (Please refer to the illustration above)

NEGATIVE: \* Two lines appear. A colored line appears in the Control region (C) and a colored line appears in the Test region (T). This negative result means that the concentrations in the urine sample are below the designated cut-off levels for a particular drug tested.

\*NOTE: The shade of the colored lines(s) in the Test region (T) may vary. The result should be considered negative whenever there is even a faint line.

POSITIVE: A colored line appears in the Control region (C) and NO line appears in the Test region (T). The positive result means that the drug concentration in the urine sample is greater than the designated cut-off for a specific drug.

**INVALID:** No line appears in the Control region (C). Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for Control line failure. Read the directions again and repeat the test with a new test panel. If the result is still invalid, contact your manufacturer.

# QUALITY CONTROL

A procedural control is included in the test. A line appearing in the control region (C) is considered an internal procedural control. It confirms adequate membrane wicking.

Control standards are not supplied with this kit. However, it is recommended that positive and negative controls be tested as good laboratory practice to confirm the test procedure and to verify proper test performance.

#### LIMITATIONS

- The Multi-Drug Rapid Test Panel provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/mass spectrometry (GC/MS) is the preferred confirmatory method.<sup>1,10</sup>
- There is a possibility that technical or procedural errors, as well as interfering substances in the urine specimen may cause erroneous results.
- Adulterants, such as bleach and/or alum, in urine specimens may produce erroneous results regardless of the analytical method used. If adulteration is suspected, the test should be repeated with another urine specimen.
- A positive result does not indicate level or intoxication, administration route or concentration in urine.
- A negative result may not necessarily indicate drug-free urine. Negative results can be obtained when drug is present but below the cut-off level of the test.
- 6. This test does not distinguish between drugs of abuse and certain medications.
- 7. A positive test result may be obtained from certain foods or food supplements.

#### [EXPECTED VALUES]

This negative result indicates that the drug concentration is below the detectable level. Positive result means the concentration of drug is above the detectable level. **[PERFORMANCE CHARACTERISTICS]** 

## Accuracy

A side-by-side comparison was conducted using the Multi-Drug Rapid Test Panel and commercially available drug rapid tests. Testing was performed on approximately 250 specimens per drug type previously collected from subjects presenting for Drug Screen Testing. Presumptive positive results were confirmed by GC/MS, LC/MS or LC-LC/MS.

Met	hod	GC/MS, LC/MS	or LC-LC/MS	0/ correspond with CC/MC		
Multi-Drug Rap	oid Test Panel	Positive	Negative	% agreement with GC/MS		
AMP	Positive	161	4	97.0%		
1,000	Negative	5	210	98.1%		
AMP	Positive	165	5	98.8%		
500	Negative	2	208	97.7%		
AMP	Positive	168	3	99.4%		
300	Negative	1	208	98.6%		
BAR	Positive	129	2	93.5%		
300	Negative	9	160	98.8%		
BAR	Positive	135	2	94.4%		
200	Negative	8	155	98.7%		
BZO	Positive	135	2	96.4%		
500	Negative	5	158	98.8%		
BZO	Positive	136	2	97.1%		
300	Negative	4	158	98.8%		
BZO	Positive	137	2	97.2%		
200	Negative	4	157	98.7%		
BZO	Positive	138	2	97.9%		
100	Negative	3	157	98.7%		
PLID	Positive	99	1	99.0%		
DUP	Negative	1	149	99.3%		
COC	Positive	120	8	97.6%		
300	Negative	3	169	95.4%		
COC	Positive	105	0	99.1%		
150	Negative	1	144	>99.9%		
COC	Positive	126	12	98.4%		
100	Negative	2	165	93.2%		
THC	Positive	127	5	97.7%		
150	Negative	3	185	97.4%		

Met	hod	GC/MS, LC/MS	or LC-LC/MS	
Multi-Drug Rap	oid Test Panel	Positive	Negative	% agreement with GC/M
THC	Positive	137	6	97.8%
50	Negative	3	184	96.8%
THC	Positive	117	9	99.2%
25	Negative	1	193	95.5%
THC	Positive	117	9	99.2%
20	Negative	1	193	95.5%
MTD	Positive	123	4	99.2%
300	Negative	1	172	97.7%
MTD	Positive	123	4	99.2%
200	Negative	1	172	97.7%
MET	Positive	165	9	>99.9%
1 000	Negative	0	176	95.1%
MET	Positivo	168	6	>00.0%
500	Nogotivo	100	176	233.376 06.79/
MET	Positive	160	5	>00.0%
300	Nogotivo	103	176	07.29/
	Desitive	120	170	97.270
	Positive	129	0	99.2%
1,000	Negative	1	180	>99.9%
MDMA	Positive	132	1	>99.9%
500	Negative	0	1/2	99.4%
MDMA	Positive	125	5	96.9%
250	Negative	4	116	95.9%
MDMA	Positive	125	5	96.9%
300	Negative	4	116	95.9%
MOP	Positive	141	6	99.3%
300	Negative	1	164	97.6%
MOP 100	Positive	142	5	>99.9%
100	Positivo	0	163	97.0%
MQL	Negative	90	1/0	99.0%
OPI	Positive	95	143	>99.9%
2000	Negative	0	145	93.5%
OPI	Positive	95	10	>99.9%
1000	Negative	0	145	93.5%
PCP	Positive	131	1	>99.9%
101	Negative	0	181	99.5%
PPX	Positive	95	3	96.0%
	Negative	4	148	98.0%
TCA	Positive	122	15	97.6%
-	Positive	3	210	93.3%
TRA	Negative		1/0	99.0%
KET	Positive	102	9	94.4%
1,000	Negative	6	133	93.7%
KET	Positive	113	9	96.6%
500	Negative	4	124	93.2%
KET	Positive	109	11	94.0%
300	Negative	7	123	91.8%
OXY	Positive	104	1	98.1%
00T	Negative	2	143	99.3%
200	Positive	6/ E	4	94.0%
COT	Positive	01 01	104	97.4%
100	Negative		152	93.0 %
FDDP	Positive	82	5	98.8%
300	Negative	1	112	95.7%
EDDP	Positive	87	6	96.7%
100	Negative	3	104	94.5%
FYL	Positive	108	10	99.1%
20	Negative	1	131	92.9%
FYL	Positive	110	13	99.1%
10	Negative	1	126	90.6%
K2-50	Positive	62	3	96.9%
	Negative	2	233	98.7%
K2-30	Positive	60	3	98.5%
ETC	Positivo	179	230	90.1%
500	Negative	4	221	97.0%
000	nogative	+		33.170

Metho	ł	GC/MS, LC/MS	or LC-LC/MS	0/ agreement with CC/MC
Drug Rapio	Test Panel	Positive	Negative	% agreement with GC/MS
ZOL	Positive	148	2	98.0%
50	Negative	3	236	99.2%
(CMD)	Positive	4	0	>99%
-(SIVIF)	Negative	0	40	>99%
ICAT	Positive	18	0	>99%
000	Negative	0	132	>99%
ИЕР	Positive	15	0	>99%
500	Negative	0	135	>99%
R-144	Positive	48	1	96.0%
25	Negative	2	49	98.0%
25 Ilowing resu	Negative ts were tabu	2 lated from these of	49 clinical studies:	

ngi

# % Agreement with Commercial Kit

	AMP	AMP	AMP	BAR	BAR	BZO	BZO	BZO	BZO		COC
	1,000	500	300	300	200	500	300	200	100	DUF	300
Positive	>99.9	>99.9	>99.9	>99.9	>99.9	>99.9	>99.9	>99.9	>99.9	>99.9	>99.9
Agreement	%	%	%	%	%	%	%	%	%	%	%
Vegative	>99.9	>99.9	>99.9	>99.9	>99.9	>99.9	>99.9	>99.9	>99.9	>99.9	>99.9
Agreement	%	%	%	%	%	%	%	%	%	%	%
otal	>99.9	>99.9	>99.9	>99.9	>99.9	>99.9	>99.9	>99.9	>99.9	>99.9	>99.9
Results	%	%	%	%	%	%	%	%	%	%	%

	COC 150	COC 100	THC 150	THC 50	THC 25	MTD 300	MTD 200	MET 1,000	MET 500	MET 300
Positive Agreement	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%
Negative Agreement	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%
Total Results	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%

	MDMA 1,000	MDMA 500	MOP 300	MOP 100	MQL	PCP	PPX	KET 1,000	KET 500	KET 300
Positive Agreement	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%
Negative Agreement	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%
Total Results	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%	>99.9%

	K2 50	K2 30	OPI 2000	OPI 1000	TCA	TRA	OXY	COT 200	COT 100	EDDP 300	EDDP 100	FYL 20
Positive Agreement	*	*	*	*	*	*	*	*	*	*	*	*
Negative Agreement	*	*	*	*	*	*	*	*	*	*	*	*
Total Results	*	*	*	*	*	*	*	*	*	*	*	*

	FYL 10	ETG 500	ZOL 50	K2+ (SMP) LC-MS/MS	THC 20	MDMA 250	MDMA 300	UR-144 25	MCAT 1000	MEP 500
Positive Agreement	*	*	*	*	*	*	*	*	*	*
Negative Agreement	*	*	*	*	*	*	*	*	*	*
Total Results	*	*	*	*	*	*	*	*	*	*

# Note: Based on GC/MS or LC-MS/MS data instead of Commercial Kit. % Agreement with GC/MS, LC/MS or LC-MS/MS

	// Agreement with CO/MO, EO/MO OF EO-MO/MO														
	AMP	AMP 500	AMP	BAR	BAR	BZO	BZO	BZO	BZO	BUP	COC				
Positive Agreement	97.0%	98.8%	99.4%	93.5%	94.4%	96.4%	97.1%	97.2%	97.9%	99.0%	97.6%				
Negative Agreement	98.1%	97.7%	98.6%	98.8%	98.7%	98.8%	98.8%	98.7%	98.7%	99.3%	95.4%				
Total Results	97.6%	98.2%	98.9%	96.3%	97.1%	97.7%	98.0%	98.0%	98.3%	99.2%	96.3%				

	COC 150	COC 100	THC 150	THC 50	THC 25	MTD 300	MTD 200	MET 1,000	MET 500	MET 300	MQL
Positive Agreement	99.1%	98.4%	97.7%	97.8%	99.2%	99.2%	98.1%	>99.9%	>99.9%	>99.9%	99.0%
Negative Agreement	>99.9%	93.2%	97.4%	96.8%	95.5%	97.7%	97.9%	95.1%	96.7%	97.2%	98.7%
Total Results	99.6%	95.4%	97.5%	97.3%	96.9%	98.3%	98.0%	97.4%	98.3%	98.6%	98.8%

	MDMA 1,000	MDMA 500	MOP 300	MOP 100	OPI 2000	PCP	KET 1,000	KET 500	KET 300	K2 50	K2 30
Positive Agreement	99.2%	>99.9%	99.3%	>99.9%	>99.9%	>99.9%	94.4%	96.6%	94.0%	96.9%	98.5%
Vegative Agreement	>99.9%	99.4%	97.6%	97.0%	93.5%	99.5%	93.7%	93.2%	91.8%	98.7%	98.7%
Fotal Results	99.7%	99.7%	97.8%	98.4%	96.0%	99.7%	94.0%	94.8%	92.8%	98.3%	98.7%

	PPX	TCA	TRA	OXY	COT 200	COT 100	EDDP 300	EDDP 100	FYL20	FYL10	ETG 500
Positive Agreement	96.0%	97.6%	99.0%	98.1%	94.6%	95.8%	98.8%	96.7%	99.1%	99.1%	97.8%
Negative Agreement	98.0%	93.3%	98.7%	99.3%	97.4%	98.1%	95.7%	94.5%	92.9%	90.6%	99.1%
Total Results	97.2%	94.9%	98.8%	98.8%	96.4%	97.2%	97.0%	95.5%	95.6%	94.4%	98.5%

	OPI	ZOL	K2+	THC	MDMA	MDMA	MCAT	MEP	UR-144
	1000	50		20	250	300	1000	500	25
Positive Agreement	94.3%	98.0%	>99%	99.2%	96.9%	96.9%	>99.9%	>99.9%	96.0%
Negative Agreement	91.3%	99.2%	>99%	95.5%	95.9%	95.9%	>99.9%	>99.9%	98.0%
Total Results	92.8%	98.7%	>99%	96.9%	96.4%	96.4%	>99.9%	>99.9%	97.0%

Clinical samples for each drug were run using each of the Multi-Drug Rapid Test Panel by an untrained operator at a professional point of care site. Based on GC/MS or LC-MS/MS data, the operator obtained statistically similar positive agreement, negative agreement and overall agreement rates as trained laboratory personnel.

Precision A study was conducted at three hospitals by untrained operators using three different lots of product to demonstrate the within run, between run and between operator precision. An identical card of coded specimens, containing drugs at concentrations of  $\pm$  50% and  $\pm$  25% cut-off level, was labeled, blinded and tested at each site. The results are given below: **AMPHETAMINE (AMP 1,000)** 

	Amphetamine	n per	Site A		Site B		Site C	
	conc. (ng/mL)	site	-	+	-	+	-	+
[	0	10	10	0	10	0	10	0
	500	10	10	0	10	0	10	0
Γ	750	10	9	1	8	2	8	2
	1,250	10	2	8	2	8	2	8
[	1,500	10	0	10	0	10	0	10
AMP	PHETAMINE (AMP 500)							
	Amphetamine	n per	Site	e A	Sit	e B	Site	еC
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	250	10	10	0	10	0	10	0
	375	10	8	2	8	2	8	2
	625	10	2	8	2	8	2	8
	750	10	0	10	0	10	0	10
AMP	PHETAMINE (AMP 300)							
	Amphetamine	n per	Site	e A	Sit	е В	Site	e C
	conc. (ng/mL)	site	-	+	-	+	•	+
	0	10	10	0	10	0	10	0
	150	10	10	0	10	0	10	0
	225	10	7	3	8	2	8	2
	375	10	2	8	2	8	2	8
Γ	450	10	0	10	0	10	0	10
BAR	BITURATES (BAR 300)							
	Secobarbital	n per	Site	eΑ	Sit	eВ	Site	еC
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	150	10	10	0	10	0	10	0
	225	10	9	1	8	2	8	2
[	375	10	2	8	1	9	2	8
	450	10	0	10	0	10	0	10
BAR	BITURATES (BAR 200)							
	Secobarbital	n per	Site	e A	Sit	е В	Site	e C
	conc. (ng/mL)	site	-	+	-	+	-	+
ſ	0	10	10	0	10	0	10	0
[	100	10	10	0	10	0	10	0
ſ	150	10	9	1	9	1	8	2
Ī	250	10	2	8	1	9	1	9

300

10 0 10 0 10 0 10

# **BENZODIAZEPINES (BZO 500)**

	Oxazenam	n ner	Site	eΑ	Sit	e B	Site	- C
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	+ 0	10	+	10	+ 0
	250	10	10	0	10	0	10	0
	230	10	0	0	10	1	10	1
	375	10	0	2	9	1	9	
	625	10	1	9	1	9	1	9
DENIZ	750	10	0	10	0	10	0	10
BENZ	ODIAZEPINES (BZO 300)		0.4		0.1	-	0.1	~
	Oxazepam	n per	Site	eΑ	Sit	ев	Site	эC
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	150	10	10	0	10	0	10	0
	225	10	9	1	9	1	9	1
	375	10	1	9	1	9	1	9
	450	10	0	10	0	10	0	10
BENZ	ODIAZEPINES (BZO 200)							
	Oxazepam	n per	Site	eΑ	Sit	eВ	Site	эC
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	100	10	10	0	10	0	10	0
	150	10	8	2	8	2	9	1
	250	10	1	- 0	1	- 0	1	a.
	200	10	0	10	0	10	0	10
BENZ		10	0	10	0	10	0	10
		n nor	Qi+	ο Δ	Qi+	e B	Si+/	- C
	Oxazepani	n per	510		310	е <b>Б</b>	310	, C
		40	-	+	-	+	-	+
- F	U	10	10	U	10	U	10	0
	50	10	10	0	10	0	10	0
_	75	10	9	1	8	2	9	1
	125	10	1	9	1	9	2	8
	150	10	0	10	0	10	0	10
BUPR	ENORPHINE (BUP)							
	Buprenorphine	n per	Site	e A	Sit	eВ	Site	эC
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	5	10	10	0	10	0	10	0
	7.5	10	9	1	8	2	8	2
	12.5	10	1	9	1	9	1	9
	15	10	0	10	0	10	0	10
COCA	INE (COC 300)							
	Benzovlecgonine	n per	Site	eΑ	Sit	eВ	Site	эC
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	150	10	10	0	10	0	10	0
	225	10	9	1	8	2	8	2
	375	10	1	9	1	9	1	9
	450	10	0	10	0	10	0	10
COCA	INE (COC 150)	10	0	10	0	10	0	10
	Benzovlecgonine	n ner	Site	<u>م</u>	Sit	eΒ	Site	- C
	conc (ng/ml)	site	-	+	-	+	-	+
⊢	0	10	10	0	10	0	10	
⊢	75	10	10	0	10	0	10	0
- F	1125	10	2	2	2	2	2	2
	112.3	10	0	2	0	2	0	2
	107.5	10	1	9	1	9		9
COC.	220	10	0	10	0	10	U	10
CUCA			Cit	o A	Ci+	o P	Ci+	
	Benzoylecgonine	n per	510	eΑ	510	еь	SILE	30
	conc. (ng/mL)	site	-	+	-	+	-	+
_	0	10	10	0	10	0	10	0
_	50	10	10	0	10	0	10	0
	75	10	9	1	9	1	9	1
	125	10	2	8	1	9	1	9
	150	10	0	10	0	10	0	10
MARI.	JUANA (THC150)				-			
	11-nor-∆ <sup>9</sup> -COOH	n per	Site	e A	Sit	е В	Site	эC
L	conc. (ng/mL)	site	-	+	-	+	-	+
L	0	10	10	0	10	0	10	0
	75	10	10	0	10	0	10	0
	112.5	10	9	1	9	1	9	1
	187.5	10	1	9	1	9	1	9
	225	10	0	10	0	10	0	10

#### м

11-nor-∧ <sup>9</sup> -COOH	n per	Site	еA	Sit	eВ	Site	еC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
25	10	10	0	10	0	10	0
37.5	10	9	1	8	2	9	1
62.5	10	1	9	1	9	1	9
75	10	0	10	0	10	0	10
ARIJUANA (THC25)	-						
11-nor-∆ <sup>9</sup> -COOH	n per	Site	e A	Sit	eВ	Site	эC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
12.5	10	10	0	10	0	10	0
18.75	10	8	2	8	2	9	1
31.25	10	1	9	1	9	2	8
37.5	10	0	10	0	10	0	10
ARIJUANA (THC20)	1						
11-nor-∆°-COOH	n per	Sit	e A	Sit	eВ	Site	еC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
10	10	10	0	10	0	10	0
15	10	9	1	8	2	9	1
25	10	2	8	1	9	2	8
30	10	0	10	0	10	0	10
ETHADONE (MTD300)	r	0.1	- 4	0.1		0:1	
Methadone	n per	SI	e A	SIL	ев	SIT	εc
conc. (lig/lile)	3110	-	+	-	+	-	+
150	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
220	10	0	2	9	0	9	0
375	10	1	9	1	9	1	9
	10	0	10	0	10	U	10
Mathadapa	n nor	Qit.	o A	Sit	o B	Sit/	
	sito	010	- A	510	- D	010	
	10	10	0	10	+ 0	10	0
100	10	10	0	10	0	10	0
		10	0	10		0	1
150	10	8	2	a 🛛	1	. u	
150	10	8	2	9	1	9	Q.
150 250 300	10 10 10	8 1 0	2 9 10	9 1 0	1 9 10	9	9
150 250 300 FTHAMPHETAMINE (MET1.000	10 10 10 10	8 1 0	2 9 10	9 1 0	1 9 10	9 1 0	9 10
150 250 300 ETHAMPHETAMINE (MET1,000 Methamphetamine	10 10 10 10	8 1 0 Site	2 9 10 e A	9 1 0 Sit	1 9 10 e B	9 1 0 Site	9 10
150 250 300 ETHAMPHETAMINE (MET1,000 Methamphetamine conc. (ng/mL)	10 10 10 10 ) n per site	8 1 0 Site	2 9 10 e A	9 1 0 Site	1 9 10 e B +	9 1 0 Site	9 10 e C +
150 250 300 ETHAMPHETAMINE (MET1,000 Methamphetamine conc. (ng/mL) 0	10 10 10 10 ) n per site 10	8 1 0 Site	2 9 10 e A +	9 1 0 Sit	1 9 10 e B + 0	9 1 0 Situ -	9 10 e C + 0
150 250 300 ETHAMPHETAMINE (MET1,000 Methamphetamine conc. (ng/mL) 0 500	10 10 10 10 ) n per site 10 10	8 1 0 Site - 10 10	2 9 10 e A + 0 0	9 1 0 Sit - 10	1 9 10 e B + 0 0	9 1 0 Site - 10 10	9 10 e C + 0 0
150           250           300           ETHAMPHETAMINE (MET1,000           Methamphetamine conc. (ng/mL)           0           500           750	10 10 10 10 ) n per site 10 10 10	8 1 0 - 10 10 9	2 9 10 e A + 0 0 1	9 1 0 Sit - 10 10 9	1 9 10 e B + 0 0 1	9 1 0 Site - 10 10 9	9 10 e C + 0 0
, 150 150 250 300 ETHAMPHETAMINE (MET1,000 Methamphetamine conc. (ng/mL) 0 500 750 1 250	10 10 10 10 ) n per site 10 10 10	8 1 0 Site - 10 10 9 1	2 9 10 e A + 0 0 1 9	9 1 0 Sitt - 10 10 9 1	1 9 10 e B + 0 0 1 9	9 1 0 Site - 10 10 9 1	9 10 e C + 0 0 1 9
	10 10 10 10 ) n per site 10 10 10 10	8 1 0 Site - 10 10 9 1	2 9 10 e A + 0 0 1 9 10	9 1 0 Sitt - 10 10 9 1 0	1 9 10 e B + 0 0 1 9 10	9 1 0 - 10 10 9 1 0	9 10 e C + 0 0 1 9 10
	10 10 10 10 10 10 10 10 10 10	8 1 0 Site - 10 10 9 1 0	2 9 10 e A + 0 0 1 9 10	9 1 0 5 10 10 9 1 0	1 9 10 e B + 0 0 1 9 10	9 1 0 Site - 10 10 9 1 0	9 10 e C + 0 0 1 9 10
150           250           300           ETHAMPHETAMINE (MET1,000           Methamphetamine           conc. (ng/mL)           0           500           750           1,250           1,500           ETHAMPHETAMINE (MET 500)	10 10 10 10 10 10 10 10 10 10	8 1 0 Situ - 10 10 9 1 0 Situ	2 9 10 e A + 0 0 1 9 10	9 1 0  10 10 9 1 0 Sit	1 9 10 e B + 0 0 1 9 10 e B	9 1 0 5it 10 10 9 1 0 Sit	9 10 • C + 0 0 1 9 10 • C
150           150           250           300           ETHAMPHETAMINE (MET1,000           Methamphetamine           conc. (ng/mL)           0           500           750           1,250           1,500           ETHAMPHETAMINE (MET 500)           Methamphetamine           conc. (ng/mL)	10 10 10 10 10 10 10 10 10 10 10 10	8 1 0 - 10 10 9 1 0 Site	2 9 10 e A + 0 0 1 9 10 e A +	9 1 0 Sitt 10 10 9 1 0 Sitt -	1 9 10 e B + 0 0 1 9 10 e B +	9 1 0 Site 10 10 9 1 0 Site	9 10 € C + 0 0 1 9 10 10 € C +

	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	250	10	10	0	10	0	10	0
	375	10	8	2	9	1	9	1
	625	10	1	9	1	9	1	9
	750	10	0	10	0	10	0	10
MET	THAMPHETAMINE (MET300)							

	1 /							
Γ	Methamphetamine	n per	Site	e A	Site	eВ	Site C	
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	150	10	10	0	10	0	10	0
	225	10	9	1	9	1	8	2
	375	10	1	9	1	9	1	9
	450	10	0	10	0	10	0	10
	150 225 375 450	10 10 10 10	10 9 1 0	0 1 9 10	10 9 1 0	0 1 9 10	10 8 1 0	

# METHYLENEDIOXYMETHAMPHETAMINE (MDMA1, 000) Ecstasy

Methylenedioxymethamphetamine	n per	SI	Site A		эΒ	Site C	
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
500	10	10	0	10	0	10	0
750	10	8	2	9	1	8	2
1,250	10	2	8	2	8	1	9
1,500	10	0	10	0	10	0	10

# METHYLENEDIOXYMETHAMPHETAMINE (MDMA 500) Ecstasy

	Methylenedioxymethamphetamine	e n per	S	ite A	Si	ев	Site	eC
	conc. (ng/mL)	site	-	+	L - T	+		+
	0	10	10	0	10	0	10	0
	250	10	10	0	10	0	10	0
	230	10	0	2	0	1	0	1
	375	10	0	2	9	1	9	1
	625	10	2	8	1	9	1	9
	750	10	0	10	0	10	0	10
ME	THYLENEDIOXYMETHAMPHETA	MINE (MD	MA 25	0) Ecst	asy			
	Methylenedioxymethamphetamine	n per	S	ite A	Sit	te B	Sit	еC
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	125	10	10	0	10	0	10	0
	107.5	10	0	0	0	4	0	0
	187.5	10	0	2	9		9	1
	312.5	10	2	8	1	9	1	9
	375	10	0	10	0	10	0	10
ME	THYLENEDIOXYMETHAMPHETA	MINE (MD	MA 30	<ol><li>Ecst</li></ol>	asy			
	Methylenedioxymethamphetamine	e n per	S	ite A	Sit	te B	Sit	еC
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	150	10	10	0	10	0	10	0
	150	10	10	0	10	0	10	0
	225	10	8	2	9	1	9	1
	375	10	2	8	1	9	1	9
	450	10	0	10	0	10	0	10
MO	RPHINE (MOP 300)							
	Morphine	n per	Sit	eА	Site	эB	Site	εС
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0 0	10	0	10	0
	150	10	10	0	10	0	10	0
	150	10	10	0	10	0	10	0
	225	10	9	1	9	1	9	1
	375	10	1	9	1	9	1	9
	450	10	0	10	0	10	0	10
MO	RPHINE (MOP 100)							
Ĩ	Morphine	n per	Sit	еA	Site	еB	Site	e C
	conc (ng/ml)	site	-	+	-	+	-	+
	0	10	10	÷	10	+	10	+ 0
	0	10	10	0	10	0	10	0
	50	10	10	0	10	0	10	0
	75	10	9	1	9	1	9	1
	125	10	1	9	2	8	1	9
	150	10	0	10	0	10	0	10
ME	THAQUALONE (MQL 300)							
	Methagualone	n per	Sit	еA	Site	эB	Site	эC
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0 0	10	0	10	0
	150	10	10	0	10	0	10	0
	150	10	10	0	10	0	10	0
	225	10	9	1	9	1	9	1
	375	10	1	9	2	8	1	9
	450	10	0	10	0	10	0	10
MO	RPHINE/OPIATE (OPI 2,000)							
	Morphine	n per	Sit	eА	Site	эB	Site	ъС
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	1 000	10	10	n n	10	0	10	0
	1,000	10	0	1	0	1	0	2
	1,500	10	9	1	9	1	0	2
	2,500	10	1	9	1	9	1	9
	3,000	10	0	10	0	10	0	10
мо	RPHINE/OPIATE (OPI 1,000)							
	Morphine	n per	Sit	eА	Site	эB	Site	эC
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	500	10	10	0	10	0	10	0
	750	10	q	1	q	1	8	2
	1 250	10	1	ó	1	ò	1	-
	1,230	10	1	9	1	9	1	9
	1,500	10	U	10	U	10	U	10
PH	ENCYCLIDINE (PCP)							
	Phencyclidine	n per	Sit	eА	Site	эB	Site	эC
	conc. (ng/mL)	site	-	+	-	+	-	+
	0	10	10	0	10	0	10	0
	40.5	10	10	0	10	0	10	0
	12.5	10	10	U	10	U	10	U
	18.75	10	8	2	9	1	8	2
	31,25	10	1	9	1	9	2	8
			•	4.0	•	40	•	40
	37.5	10	()	10	0	10	()	10

37.5 PROPOXYPHENE (PPX)

Propozyphene	n ner	Site	еA	Sit	еB	Site	еC
conc (ng/ml)	site	-		-	- <sup>-</sup>	-	
0	10	10	+ 0	10	+	10	-
150	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225	10	8	2	9	1	9	1
375	10	1	9	1	9	2	8
450	10	0	10	0	10	0	10
TRICYCLIC ANTIDEPRESSANTS (TO	CA)						
Nortriptyline	n per	Site	eΑ	Sit	eВ	Site	еC
conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
500	10	10	0	10	0	10	0
750	10	Ω	2	0 0	2	9	2
130	10	0	2	0	2	0	2
1,250	10	1	9	1	9	2	8
1,500	10	0	10	0	10	0	10
Tramadol (TRA)					_		
Tramadol conc. (ng/ml.)	n per	Site	еA	Sit	eВ	Site	еC
mamador cone: (ng/mE)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
50	10	10	0	10	0	10	0
75	10	9	1	8	2	8	2
125	10	1	q	1	9	2	8
150	10	0	10	0	10	0	10
KETAMINE (KET1 000)	10	0	10	0	10	0	10
KETAMINE (KETT, 000)		0:4	• ^	0:4	• D	0:4	
Ketamine conc. (ng/mL)	n per	SIL	- A	510	D D	310	
,	SITE	-	+	-	+	-	+
0	10	10	0	10	0	10	0
500	10	10	0	10	0	10	0
750	10	9	1	8	2	9	1
1,250	10	1	9	1	9	2	8
1,500	10	0	10	0	10	0	10
KETAMINE (KET500)							
(	n ner	Site	еA	Sit	еB	Site	еC
Ketamine conc. (ng/mL)	site	-	<u>т</u>	-	-	-	
0	10	10	0	10	+ 0	10	-
0	10	10	0	10	0	10	0
250	10	10	0	10	0	10	0
375	10	9	1	9	1	8	2
625	10	1	9	1	9	2	8
750	10	0	10	0	10	0	10
KETAMINE (KET300)		-		-			
Kotamino conc. (ng/ml.)	n per	Site	eА	Sit	eВ	Site	еC
Retarrine conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225	10	9	1	9	1	9	1
375	10	1	q	1	9	2	8
450	10	0	10	0	10	0	10
Orvicadana (OXV)	10	Ŭ	10	Ŭ	10	0	10
	n nor	Qi+	<u>م</u>	Si+	≏ B	Si+	- C
Oxycodone conc. (ng/mL)	n per	010	5 A	010	е D	310	
0	3110	-	+	-	+	-	+
U	10	10	U	10	U	10	0
50	10	10	Ű	10	0	10	0
75	10	9	1	9	1	9	1
125	10	1	9	1	9	2	8
150	10	0	10	0	10	0	10
Cotinine (COT 200)							
	n per	Site	еA	Sit	eВ	Site	еC
Counine conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
100	10	10	0	10	0	10	0
150	10	9	1	9	1	9	1
250	10	1	0	1	0	2	0
230	10	1	9 10	0	9 10	2	10
300		U	10	U	10	U	10
	10						
COTININE (COT 100)	10	<b>^</b>		ċ	- D	<b>~</b> ··	
Cotinine conc. (ng/mL)	n per	Site	e A	Sit	eВ	Site	
COTININE (COT 100) Cotinine conc. (ng/mL)	n per site	Site	e A +	Site	e B +	Site	+
COTININE (COT 100) Cotinine conc. (ng/mL) 0	n per site 10	- 10	e A + 0	Site - 10	e B + 0	- 10	+
COTININE (COT 100) Cotinine conc. (ng/mL) 0 50	n per site 10 10	Site - 10 10	e A + 0 0	Site - 10 10	e B + 0 0	Site - 10 10	+ 0 0
COTININE (COT 100) Cotinine conc. (ng/mL) 0 50 75	n per site 10 10 10	Site - 10 10 9	e A + 0 0 1	Site - 10 10 9	e B + 0 0 1	Site - 10 10 9	+ 0 0
COTININE (COT 100) Cotinine conc. (ng/mL) 0 50 75 125	n per site 10 10 10 10	Site - 10 10 9 1	e A + 0 0 1 9	Site - 10 10 9 1	e B + 0 0 1 9	Site - 10 10 9 2	+ 0 0 1 8
COTININE (COT 100) Cotinine conc. (ng/mL) 0 50 75 125 150	n per site 10 10 10 10 10	Site - 10 10 9 1 0	e A + 0 0 1 9 10	Site - 10 10 9 1 0	e B + 0 1 9 10	Site - 10 10 9 2 0	+ 0 0 1 8 10
COTININE (COT 100) Cotinine conc. (ng/mL) 0 50 75 125 150 2-ETHYLIDENE-1.5-DIMETHYL-3.3-D	n per site 10 10 10 10 10 10	Site - 10 10 9 1 0 PYRR0	e A + 0 1 9 10	Site - 10 10 9 1 0 E (EDI	e B + 0 1 9 10 <b>DP 300</b>	Site - 10 10 9 2 0	+ 0 0 1 8 10

	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
150	10	10	0	10	0	10	0
225	10	8	2	9	1	9	1
275	10	1	0	2	0	1	0
	10	0	3	2	10	0	3
	10		10		10	0	10
2-EINTLIDENE-1,3-DIMEINTL-3,3-1					<u>, D</u>	0.11	
EDDP conc. (ng/mL)	n per	310	eΑ	310	50	310	
	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
50	10	10	0	10	0	10	0
75	10	8	2	9	1	9	1
125	10	1	9	1	9	1	9
150	10	0	10	0	10	0	10
FENTANYL (FYL20)							
Norfesterul sens (sa/ml.)	n per	Sit	еA	Site	эB	Site	эC
Norrentanyi conc. (ng/mL)	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
10	10	10	0	10	0	10	0
15	10	8	2	a	1	a	1
15	10	0	2	3	0	9	0
25	10	1	9	1	9	2	0
	10	U	10	U	10	U	10
ENTANTE (FTE10)		0.	- 4	0.1		0.1	
Norfentanyl conc. (ng/mL)	n per	Sit	eΑ	Site	εВ	Site	эC
(	site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
5	10	10	0	10	0	10	0
7.5	10	8	2	9	1	9	1
12.5	10	1	9	1	9	2	8
15	10	0	10	0	10	0	10
K2-50							
Synthetic Marijuana	nner	Sit	eΑ	Site	e B	Site	ъ С
Concentration (ng/ml)	Site	010		010		Ont	-
	40	-	Ŧ	-	т О	-	T
U	10	10	0	10	0	10	0
25	10	10	0	10	0	10	0
37.5	10	8	2	9	1	9	1
62.5	10	1	9	1	9	2	8
75	10	0	10	0	10	0	10
K2-30							
Synthetic Marijuana	nner	Sit	еA	Site	еB	Site	эC
Concentration (ng/ml)	Site	-		-	-	-	
0	10	10	0	10	,	10	0
0	10	10	0	10	0	10	0
15	10	10	0	10	0	10	0
22.5	10	8	2	9	1	9	1
37.5	10	1	9	1	9	2	8
45	10	0	10	0	10	0	10
ETG-500	-						-
Synthetic Marijuana	nner	Sit	e A	Site	eВ	Site	эC
Concentration (ng/mL)	Site	-	+	-	+	-	+
	10	10	0	10	,	10	~
0	10	10	0	10	0	10	0
250	10	10	U	10	U	10	0
375	10	6	4	7	3	6	4
625	10	2	8	1	9	1	9
750	10	0	10	0	10	0	10
K2+(SMP)							
AB-PINACA metabolite	nper	Sit	e A	Site	eВ	Site	эC
Concentration (ng/mL)	Site	-	+	-	+	-	+
0	10	10	O	10	, O	10	
	10	10	0	10	0	10	0
5	10	10	Ú	10	U	10	0
7.5	10	9	1	9	1	9	1
12.5	10	1	9	1	9	2	8
15	10	0	10	0	10	0	10
ZOL-50	-						-
	1	Sit	еA	Site	eВ	Site	эC
Zolpidem Concentration	n per		1	0.0	_	0.0	
(ng/mL)	Site	-	+	-	+	-	+
0	10	10	0	10	0	10	0
25	10	10	0	10	n n	10	n
20	40	.0		6	4	6	4
37.5	10	o í	4	0	4	0	4
62.5	10	1	9	1	9	1	9

10 0 10 0 10 0 10

75

Inclusion (ng/mL)         Title         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +		Methcathir	one	<u> </u>	nce	ontra	ation	.	n	nor		Si	te A		Si	te B			Site	С	
0         1		Metricatini	(na/i	nĽ	)	51111 6	1101	'	S	ite		-	4		-		÷		-	+	
0         10         10         10         10         10         10         10					<i>'</i>				-				<u> </u>			_	<u>.</u>			<u> </u>	_
500         10         10         0         10         0         10         0         10         0           MEP-500         100         10         10         0         10         10         0         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10			0						1	0		10	C	)	10		0	1	0	0	
750         10         7         3         7         3         8         2           1250         10         1         0         10         0         10         0         10           MEP-500         nper (ng/mL)         nper Site         Site         A         Site         Site         C           0         10         10         0         10         0         10         0         10         0           500         10         1         0         10         0         10         0         10         0           1250         10         1         9         1         8         2         8           100         10         0         10         0         10         0         10         0         10         0         10           112.5         10         0         10         0         10         0         10         0         10         0         10         0         10         0         10         0         10         0         10         0         10         0         10         0         10         10         0         10         10 <t< td=""><td></td><td></td><td>50</td><td>0</td><td></td><td></td><td></td><td></td><td>1</td><td>0</td><td></td><td>10</td><td>C</td><td>)</td><td>10</td><td></td><td>0</td><td>1</td><td>0</td><td>0</td><td></td></t<>			50	0					1	0		10	C	)	10		0	1	0	0	
1250         10         1         9         1         9         2         8           MEP-500         Mephedrone Concentration (ng/mL)         n per Site         Site         A         Site         Site         C         +         -         -         +         -         -         +         -         +         -         +         -         +			75	0					1	0		7	3	3	7		3	8	В	2	
HEP-500         10         0         10         0         10         0         10         0         10           Mephedrone Concentration (ng/mL)         n per (ng/mL)         Site A         Site A         Site B         Site C           0         10         10         0         10         0         10         0         10         0           500         10         7         3         7         3         8         2           1250         10         1         9         1         9         2         8           WR-144 5-Pentanoic acid metabolite Concentration (ng/mL)         n per 37.5         Site A         Site A         Site B         Site C           0         10         10         0         10         0         10         0         10           12.5         10         9         1         8         2         9         1           37.5         10         9         1         8         2         9         1           37.5         10         0         10         0         10         0         10         0         10           Concentration         1,000         30			12	50					1	0		1	ç	)	1		9	1	2	8	
MEP-500         Image: Concentration (ng/mL)         n per mean         Site A         Site B         Site C           0         10         10         0         10         10         0         10         0           10         10         10         0         10         0         10         0         10         0           10         10         0         10         0         10         0         10         0           1250         10         1         9         1         9         2         8           1500         10         0         10         0         10         0         10         0         10           12.5         10         10         0         10         0         10         0         10         0         10         0         10         0         10         0         10         0         10         0         10         0         10         0         10         0         10         0         10         0         10         0         10         0         10         0         10         10         10         10         0         10         10			150	00					1	0		0	1	0	0	1	10	(	)	10	-
Dec         Mephedrone Concentration (ng/mL)         n per Site         Site A         Site B         Site C           0         10         10         0         10         0         10         0         0           500         10         10         0         10         0         10         0         10         0           1250         10         1         9         1         9         2         8           UR-144 5-Pentanoic acid metabolite Concentration (ng/mL)         n per Site         Site A         Site B         Site C           12.5         10         10         10         0         10         0         10         0           12.5         10         0         10         0         10         0         10         0           12.5         10         0         10         0         10         0         10         0         10           37.5         10         0         10         0         10         0         10         0         10           0         30.0         30         30         30         30         20         20         10         10           12.5 </td <td>ME</td> <td>P-500</td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>-</td> <td></td> <td></td> <td>•</td> <td>1 .</td> <td>× .</td> <td>Ŭ</td> <td>_</td> <td></td> <td></td> <td><u> </u></td> <td></td> <td></td>	ME	P-500	-						-			•	1 .	× .	Ŭ	_			<u> </u>		
Mephedrone Concentration (ng/mL)         n per Site         -         +         +<												Si	to A		Si	to B		1	Sito	C	7
Image: constraint of the second sec		Mephedro	one (	Cor	ncei	ntrat	ion		n	per	-	0			0		,		Sile	C	_
0         10         10         10         10         0         10         0         10         0           750         10         7         3         7         3         7         3         8         2           1250         10         1         9         1         9         2         8           1500         10         10         0         10         10         10			(ng/ı	mL)	)				S	ite		-	+	-	-		+		-	+	
500         10         0         10         10         10         10         10         10         10         10         10         10         10         10         10 <td></td> <td></td> <td>0</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>1</td> <td>0</td> <td></td> <td>10</td> <td>0</td> <td>)</td> <td>10</td> <td></td> <td>0</td> <td>1</td> <td>0</td> <td>0</td> <td>-</td>			0						1	0		10	0	)	10		0	1	0	0	-
300         10         10         10         10         0         10         0         10         0           1250         10         1         9         1         9         2         8           1500         10         0         10         0         10         0         10         0         10         0           UR-144 -25         UR-144 5-Pentancic acid metabolite Concentration (ngmL)         n per Site         Site A         Site B         Site C         Site C           0         10         10         0         10         0         10         0         10         0           12.5         10         10         0         10         10         0         10         0           31.25         10         0         10         1         9         1         8         2         9         1           37.5         10         0         10         10         0         10         0         10         0         10         0         10         0         10         10         10         0         10         10         10         10         10         10         10         10			50	0				-	- 1		-	10		, ,	10	+	0	1	0	0	-
1250         10         1         3         1         3         8         2           UR-144-25         100         10         0         100         0         100         0         100         0         100         0         100         0         100         0         100         0         100         100         100         0         100         100         100         0         100         100         0         100         100         100         0         100         100         0         100         100         0         100         100         100         0         100<			75	0						0		10	U C	,	10	_	0		0	0	_
1250         10         1         9         1         9         2         8           1500         10         0         10         0         10         0         10         0         10           UR-144 - 25         UR-144 5-Pentancic acid metabolite Concentration (ngmL)         n per Site         Site A         Site B         Site C           0         10         10         10         10 <td></td> <td></td> <td>75</td> <td>0</td> <td></td> <td></td> <td></td> <td></td> <td>1</td> <td>0</td> <td></td> <td>7</td> <td>3</td> <td>3</td> <td>7</td> <td>_</td> <td>3</td> <td>5</td> <td>3</td> <td>2</td> <td></td>			75	0					1	0		7	3	3	7	_	3	5	3	2	
Image: 100         10         0         10         0         10         0         10           UR-144 25         Image: 100			12	50					1	0		1	9	)	1		9	4	2	8	
UR-144 -25         Site			150	00					1	0		0	1	0	0	1	10	(	C	10	
UR-144 5-Pentanoic acid (ng/mL)         n per Site         Site A         Site B         Site C           0         10         10         0         0         0         0         10         0         10         0         10         0         10         0         0         0         0         0         0	UR	-144 -25																			
metabolic Concentration (ng/mL)         In period Site         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         +         +         +         +         +         +         +         +         +         +         +         +         +         +         +         +         1         0         1         0         1         0         1         0         1         0         1         0         1         0         1         0         1         0         1         0         1         0         1         0         1         0         1         0         1         0         1         0         1         0         1         0         1         0         1         1         1         1         1         1         1         1         1         1         1         1         1 <td></td> <td>UR-144</td> <td>5-Pe</td> <td>nta</td> <td>noi</td> <td>c ac</td> <td>id</td> <td></td> <td></td> <td></td> <td></td> <td>Si</td> <td>te A</td> <td></td> <td>Si</td> <td>te B</td> <td></td> <td></td> <td>Site</td> <td>С</td> <td></td>		UR-144	5-Pe	nta	noi	c ac	id					Si	te A		Si	te B			Site	С	
(ng/mL)         Site         -         +         +         0         0		metaboli	te C	ond	en	tratio	on		n	per			1			1				-	-
0         10         10         0         10         0         10         0           12.5         10         10         0         10         0         10         0         10         0           18.75         10         0         10         1         9         1         9         1         9           31.25         10         0         10         1         9         1         9           Advg-free urine pol was spiked with drugs at the listed concentrations.         The results are summarized below.         BAR         BZO         BZO <td></td> <td></td> <td>(ng/ı</td> <td>mL)</td> <td>)</td> <td></td> <td></td> <td></td> <td>3</td> <td>ne</td> <td></td> <td>-</td> <td>+</td> <td>-</td> <td>-</td> <td></td> <td>+</td> <td></td> <td>-</td> <td>+</td> <td></td>			(ng/ı	mL)	)				3	ne		-	+	-	-		+		-	+	
12.5         10         10         0         10         0         10         0           31.25         10         0         10         1         8         2         9         1           31.25         10         0         10         1         9         1         9         1         9           37.5         10         0         10         0         10         0         10         0         10           Adrug-free urine pool was spiked with drugs at the listed concentrations. The results are summarized below.         Drug         AMP         AMP         AMP         AMP         200         500         300         200         10         0         10         0         10         0         10         0         30         200         10         30         0         30         200         10         30         0         30         0         30         0         30         0         30         0         30         0         30         0         30         0         30         0         30         0         30         0         30         0         30         0         30         0         30         0			0	)					1	0		10	0	)	10		0	1	0	0	7
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			12	.5				$\neg$	1	0		10	1	)	10	1	0	1	0	0	-
10.73         10         3         1         0         2         9         1           31.25         10         0         10         0         10         0         10         0         10           Adug-free urine pool was spiked with drugs at the listed concentrations. The results are summarized below.         Drug         AMP         AMP         AMP         BAR         BAR         BAR         BZO         BZO         BZO         BZO         Concentration         1.000         500         300         200         500         300         200         300         200         300         200         300         200         300         300         0         30			10	75				-+	_		+	0		-	2	+	2	+	-	1	-
31.25         10         0         10         1         9         1         9           Analytical Sensitivity           A drug-free urine pool was spiked with drugs at the listed concentrations. The results are summarized below.           Drug         AMP         AMP         AMP         BAR         BAR         BZO         BZO         BZO         BZO         Io0         100         0         100         0         100         Curotift Range         -         +         +         +         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +         -         +			10.	10				_	1	U	_	3	+		0	+	~	$\vdash$		1	-
Jo         O         IO         O         IO         O         IO         O         IO           Analytical Sensitivity           A drug-free urine pool was spiked with drugs at the listed concentrations. The results are summarized below.           Drug         AMP         AMP         AMP         BAR         BAR         BZO			31.	25					1	0		0	1	υ	1	1_	9	1	1	9	_
Analytical Sensitivity           A drug-free urine pool was spiked with drugs at the listed concentrations. The results are summarized below.           Drug         AMP         AMP         BAR         BAR         BZO         <			37	.5					1	0		0	1	0	0	1	10	(	0	10	
Drug Concentration         AMP         AMP         AMP         AMP         BAR         BAR         BZO																					
A drug-free urine pool was spiked with drugs at the listed concentrations. The results are summarized below.         Drug Concentration Cut-off Range       AMP       AMP       AMP       BAR       BAR       BAR       BZO       BZO       BZO       BZO       BZO       BZO       BZO       DIO         Cut-off       30       0       30								Ana	lyti	cal	Ser	siti	/ity								
Summarized below.         Drug Concentration 1,000         AMP 500         AMP 300         AMP 300         BAR 300         BAR 200         BAR 500         BZO 500         BZO 300         CD 200         BZO 500         BZO 300         200         100           Cut-off 9% Cut-off 140         10         30         30         30         30         30         30         30         30         30         30         30         30         30         30         30         30         30         30	Ac	drug-free urine	e poo	sl	Nas	spi	ked	wit	n dr	ugs	s at	the	liste	d co	ncer	ntrat	ions	5. TI	he re	esult	s are
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	sur	nmarized belo	w.	_	-																
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		Drug	AN	P		AMP	' I I	AMI		B/	AR	B	AR	B2	20	B	20		3ZO	В	20
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	C	oncentration	1,0	00	_	500	_	300	)	3	00	2	00	50	00	30	00	-	200	1	00
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	C	ut-off Range	-	+	-		F _	-	+	-	+	-	+	-	+	-	+	-	+	-	+
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$		0% Cut-off	30	0	3	0 (	) 3	30	0	30	0	30	0	30	0	30	0	30	) 0	30	0
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$		50% Cut-off	30	0	3	0 0	) 3	30	0	30	0	30	0	30	0	30	0	30	0 0	30	0
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	-)	25% Cut-off	27	3	2	6 4	1 2	27	3	27	3	26	4	27	3	27	3	27	7 3	27	3
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$		Cut-off	14	16	1	5 1	5 1	5 '	15	16	14	15	15	15	15	14	16	14	1 16	3 15	15
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	+	25% Cut-off	3	27	1 3	1 2	7	4 2	26	4	26	3	27	4	26	3	27	3	27	7 3	27
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		50% Cut-off	0	30	0	1 3	0	0 1	30	0	30	0	30	0	30	0	30	0	30	1 0	30
Drug Concentration Cut-off Range         BUP 30         COC 30         COC 150         COC 150         COC 150         COC 150         THC 150         THC 50         THC 25         MTD 300           - 0% Cut-off         30         0         30         30	+ 1	200% Cut-off	0	30		1 3	0		20	0	30	0	30	0	30	0	30	0	30		30
Drug Concentration Cut-off Range         BUP -         COC 300         COC 150         COC 150         COC 150         THC 150         THC 50         THC 25         MTD 300           0% Cut-off         30         0         30         30         30         30         30         30 <td>Ŧ.</td> <td>500% Cut-011</td> <td>0</td> <td>30</td> <td></td> <td>, 3</td> <td>U</td> <td>0</td> <td>50</td> <td>0</td> <td>30</td> <td>0</td> <td>30</td> <td>0</td> <td>30</td> <td>0</td> <td>30</td> <td>0</td> <td>30</td> <td>0</td> <td>30</td>	Ŧ.	500% Cut-011	0	30		, 3	U	0	50	0	30	0	30	0	30	0	30	0	30	0	30
Drug Concentration Cut-off Range         BUP -         COC -         CU         F         -         +         -	-	_	- 1				00	-	~~	~		00			· · ·	TUC			10		-
Cut-off Range         -         +         1         <		Drug		ΒU	Ρ				150		5			150		EO	·	11		111	00
Cutoff         30         0         30		Sut off Bongo	_	1			1.	-	150			100	-	150	_	50		2	.5	3	00
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$			-	_	+	-	+		-	+	-	+	-	+	-		+	-	+	-	+
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$		0% Cut-off	30	J	0	30	0	) 3	0	0	30	0	30	) ()	3	0	U	30	0	30	0
-25% Cut-off         26         4         27         3         20         30         0         30         30         30         30		-50% Cut-off	30	C	0	30	0	) 3	0	0	30	0	30	) 0	3	0	0	30	0	30	0
Cut-off         14         16         15         15         15         15         15         15         15         15         15         15         15         15         15         15         15         14         16         14         16         15         15         15         15         15         15         15         15         15         15         15         16         14         16         15         15         15         15         15         15         15         15         15         16         14         16         14         16         15         15         15         15         15         15         16         14         16         15         15         15         15         15         15         15         15         15         15         15         15         15         15         15         15         15         15         15         16         14         16 <t< td=""><td></td><td>-25% Cut-off</td><td>20</td><td>6</td><td>4</td><td>26</td><td>4</td><td>2</td><td>7</td><td>3</td><td>27</td><td>3</td><td>27</td><td>/ 3</td><td>2</td><td>6</td><td>4</td><td>27</td><td>3</td><td>27</td><td>3</td></t<>		-25% Cut-off	20	6	4	26	4	2	7	3	27	3	27	/ 3	2	6	4	27	3	27	3
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$		Cut-off	14	4	16	15	1	5 1	5	15	16	14	15	5 1	5 1	4 1	6	14	16	15	15
+50% Cut-off         0         30         30 </td <td></td> <td>+25% Cut-off</td> <td>3</td> <td></td> <td>27</td> <td>3</td> <td>2</td> <td>7 3</td> <td>3</td> <td>27</td> <td>4</td> <td>26</td> <td>5 4</td> <td>26</td> <td>3 3</td> <td>2</td> <td>27</td> <td>3</td> <td>27</td> <td>3</td> <td>27</td>		+25% Cut-off	3		27	3	2	7 3	3	27	4	26	5 4	26	3 3	2	27	3	27	3	27
+300% Cut-off         0         30         100           Cut-off         30         0         30		+50% Cut-off	0	1	30	0	3	0 0	)	30	0	30	) 0	30	) (	) 3	30	0	30	0	30
Drug Concentration Cut-off Range         MTD +         IMET +         MET +         MET +         MDMA +         MDMA S00         MOP S00         S00         MOP S00         MOP S00         MOP S00         MOP S00         MOP S00         S00         MOP S00         S00         MOP S00         S00         MOP S00         S00         S00 <t< td=""><td>+</td><td>-300% Cut-off</td><td>0</td><td></td><td>30</td><td>0</td><td>3</td><td>0 0</td><td>)</td><td>30</td><td>0</td><td>30</td><td>) 0</td><td>30</td><td>) (</td><td>) 3</td><td>30</td><td>0</td><td>30</td><td>0</td><td>30</td></t<>	+	-300% Cut-off	0		30	0	3	0 0	)	30	0	30	) 0	30	) (	) 3	30	0	30	0	30
Drug Concentration         MTD 200         MET 1,000         MET 500         MET 300         MDMA 1,000         MDMA 500         MOP 300         MOP 100           Cut-off         30         030         030         030         030         030         100           - t + - + - + - + - + - + - + - + - + -				-		-	Ť				÷									÷	1
Concentration Cut-off Range         200         1,000         500         300         1,000         500         300         100           Cut-off Range         -         +         16         15         15         15         15         15         15         16         14         16         15         <		Drug	М	TD		MF	Т	М	ΕT	T	MET	гТ	MD	MA	М	DM/	A	МС	)P	M	)P
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	6	Concentration	2	00		1,0	00	5	00	1	300		1,0	000		500	1	30	00	10	00
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Ì	Cut-off Range	-	T.	+	- 1	+	-	+	1.	. T	+	-	+	-	1	+ T	-	+	-	+
Drug         OPI         PCP         PPX         TCA         TRA         KET         KET         KET           Out-off         30         0         30         30	F	0% Cut-off	30	1	n l	30	0	30	, O	2	0	0	30	, U	30			30	0	30	0
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	⊢	-50% Cut-off	20	$\pm$	ř t	30	0	20	0	1 3	0	<del>.</del>	20		20			30	0	30	0
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	-	2E0/ Cut-off	30	+	4	20	0	25	5	13	5	5	30	4	30	++	-	30 25	5	27	0
Cut-orr         14         16         14         16         15         15         15         15         14         16         15         16         14           +25% Cut-off         3         27         4         26         4         26         5         25         4         26         3         27         4         26         5         25         4         26         3         27         4         26         4         26         5         25         4         26         3         27         4         26         3         27         4         26         3         27         4         26         5         25         4         26         3         27         4         26         3         27         4         26         3         27         4         26         3         27         4         26         3         27         4         26         3         27         4         26         3         27         4         26         3         20         30         0         30         30         30         30         30         30         30         30         30         30         30	-	-23% Cut-off	26	1	+	20	4	25	0	12	:) -	0	20	4	25		)	20	5	21	3
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		Cut-off	14	1	6	14	16	15	15	1	5	15	15	15	14	1	bi	15	15	16	14
+50% Cut-off         0         30         0 <td>Ŀ</td> <td>+25% Cut-off</td> <td>3</td> <td>2</td> <td>27</td> <td>3</td> <td>27</td> <td>4</td> <td>26</td> <td>4</td> <td>4 :</td> <td>26</td> <td>5</td> <td>25</td> <td>4</td> <td>2</td> <td>6</td> <td>3</td> <td>27</td> <td>4</td> <td>26</td>	Ŀ	+25% Cut-off	3	2	27	3	27	4	26	4	4 :	26	5	25	4	2	6	3	27	4	26
+300% Cut-off         0         30         30         0         30         0         30         0         30         0         30         0         30         0         30         0         30         30         30         30         3	-	+50% Cut-off	0	3	0	0	30	0	30	(	o ∏∶	30	0	30	0	3	0	0	30	0	30
Drug Concentration Cut-off Range         OPI 2000         PCP         PPX         TCA         TRA         KET 1,000         KET 500         KET 300         KET 300 <td>+</td> <td>-300% Cut-off</td> <td>0</td> <td>3</td> <td>0</td> <td>0</td> <td>30</td> <td>0</td> <td>30</td> <td>(</td> <td>) :</td> <td>30</td> <td>0</td> <td>30</td> <td>0</td> <td>3</td> <td>0</td> <td>0</td> <td>30</td> <td>0</td> <td>30</td>	+	-300% Cut-off	0	3	0	0	30	0	30	(	) :	30	0	30	0	3	0	0	30	0	30
Drug Concentration         OPI 2000         PCP         PPX         TCA         TRA         KET 1,000         KET 500         KET 300           Cut-off Range         -         +         +         +         +         +         -         +         -         +         -         +         10         0         30         0	<u> </u>						-									-			-		
Concentration Cut-off Range         2000         PCP         PPX         ICA         IRA         1,000         500         300           Cut-off Range         -         +         -		Drug	(	DPI		-	20	Τ.		,	-	~ ^	- 1	<b>D</b> A	ł	KET	T	KE	Т	K	T
Cut-off Range         -         +         -         <	C	Concentration	2	000	)	Р	JP	1	РРХ		10	СA	1 T	ĸА	1	,000		50	00	30	00
0% Cut-off         30         0         30         30         0         30         0 <td>Ì</td> <td>Cut-off Range</td> <td><b>—</b></td> <td>T</td> <td>+</td> <td>-</td> <td>+</td> <td>-</td> <td></td> <td>+</td> <td>-</td> <td>+</td> <td>-</td> <td>+</td> <td>-</td> <td>1</td> <td>+ T</td> <td>-</td> <td>+</td> <td>-</td> <td>+</td>	Ì	Cut-off Range	<b>—</b>	T	+	-	+	-		+	-	+	-	+	-	1	+ T	-	+	-	+
-50%         Cut-off         20         0         0         30	F	0% Cut-off	30	+	0	30	, O	21		0	30	i o	30	0	30			30	0	30	0
-cov o cut-off         35         0         35         0         35         0         30	⊢	-50% Cut off	200	+	0	20	0	2	1	0	20	~	200		30			30	0	20	0
-zo% cut-off         2/         3         20         4         2/         3         25         5         2/         3         26         4         2/         3         26         4         2/         3         26         4         2/         3         26         4         2/         3         26         4         2/         3         26         4         2/         3         26         4         2/         3         26         4         2/         3         26         4         2/         3         26         4         2/         3         26         4         2/         3         26         4         2/         3         26         4         2/         3         26         4         2/         3         26         4         2/         3         26         4         26         3         27         4         26         3         27         4         26         3         27         4         26         3         0         30         0         30         0         30         0         30         0         30         0         30         0         30         0         30         0 <td>-</td> <td>-50% Cut-Off</td> <td>30</td> <td>+</td> <td>0</td> <td>30</td> <td>0</td> <td>3</td> <td></td> <td>0</td> <td>30</td> <td></td> <td>30</td> <td>0</td> <td>30</td> <td></td> <td><u>'</u></td> <td>JU 27</td> <td>0</td> <td>30</td> <td>U</td>	-	-50% Cut-Off	30	+	0	30	0	3		0	30		30	0	30		<u>'</u>	JU 27	0	30	U
Cut-off         15         15         14         16         16         14         16         16         14         16         16         14         16         14         15         15         14         16           +25% Cut-off         4         26         3         27         4         26         3         27         4         26           +50% Cut-off         0         30         0		-25% Cut-off	27	1	3	26	4	2	1	3	25	5	27	3	26	) <sup>2</sup>	+ 13	27	3	26	4
+25% Cut-off         4         26         3         27         4         26         3         27         4         26         3         27         4         26           +50% Cut-off         0         30         30         0		Cut-off	15	1	15	14	16	1	4   1	16	16	14	14	16	16	5 1	4	15	15	14	16
+50% Cut-off 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0	-	+25% Cut-off	4	2	26	3	27	4	2	26	3	27	4	26	4	2	6	3	27	4	26
+300% Cut-off 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0	-	+50% Cut-off	0	3	30	0	30	0	3	30	0	30	0	30	0	3	0	0	30	0	30
	+	-300% Cut-off	0	12	30	0	30	0		30	0	30	0	30	0	3	0	0	30	0	30

MCAT-1000

Drug	M	QL	0	XY	C		C	01	ED	DP	ED	DP	F	YL	F	YL
Concentration		~-	•		2	00	1	00	- 30	00	10	00	2	20	1	0
Cut-off Range	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	27	3	27	3	27	3	27	3	27	3	27	3	27	3	27	3
Cut-off	15	15	16	14	15	15	16	14	16	14	16	14	16	14	16	14
+25% Cut-off	3	27	4	26	4	26	4	26	4	26	4	26	3	27	3	27
+50% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	30	0	30	0	30	0	30	0	30	0	30
	v	00	v	00	v	00	v	00	U	00	U	00	v	00	v	00
Drug	K	2	K	2	ET	G	Kź	2+	ZC	)L	0	Ы	TH	łC	MD	MA
Concentration	5	0	3	0	50	00	(SN	AP)	5	0	10	00	2	0	25	50
Cut-off Range	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+
0% Cut-off	30	0	30	0	20	0	30	0	30	0	30	0	30	0	30	0
-50% Cut-off	30	0	30	0	20	0	30	0	30	0	30	0	30	0	30	0
-25% Cut-off	27	3 3	27	3	18	2	27	3	27	3	27	3 3	27	3 3	25	5
Cut-off	16	14	16	14	12	8	15	15	15	15	15	15	13	17	14	16
LOEV Cut off	2	14	201	14	2	17	3	27	13	26	15	10	13	26	14	26
+23% Cut-011	3	21	3	21	0	20	0	20	4	20	4	20	4	20	4	20
+50% Cut-off	0	30	0	30	0	20	0	30	0	30	0	30	0	30	0	30
+300% Cut-off	0	30	0	30	0	20	0	30	0	30	0	30	0	30	0	30
				A.T.												
Drug	MD	MA	MC	AI	ME	=P	UR-	144								
Cut-off Pango	30	10	10	00	50	10		5								
	- 20	T 0	-	T	-	T	20	0								
E00/ Cut off	30	0	30	0	30	0	30	0								
-50% Cut-off	30	0	30	0	30	0	30	0								
-25% Cut-off	25	5	27	3	21	3	19	11								
Cut-off	14	16	14	16	14	16	12	18								
+25% Cut-off	4	26	4	26	4	26	0	30								
+50% Cut-off	0	30	0	30	0	30	0	30								
+300% Cut-off	0	30	0	30	0	30	0	30								
			(1	ng/m AMP	L) HET	AMI	NE (A	AMP	1,00	0)			(	ng/m	IL)	
D,L-Amphetamine	e sulf	ate	2	00			Ph	ente	rmine	Э			8	300		
Amphetamine			2	5,00	0		Ma	aproti	line				Ę	50,00	0	
<ul> <li>±) 3,4-Methylene</li> </ul>	edioxy	'	4	00			Me	ethox	yphe	nam	ine		6	<u>5,000</u>		
amphetamine							D	Ampl	netar	mine			1	,000		
Amphatam'r	0.011	ote	-		THE	IAM		AIVIP	500	<u> </u>			Ι.	100		
J,L-Amphotomine	e suit	ale		2 50	0		Ph	101110	imne	3			-		0	
	diov	,		∠,30	U		IVI2	apiOt	vnho	nam	ine		-	3 000	U	
amphetamine	uuxy		2	00			D-	Amn	netar	nine			-	500 500		
			1	АМ	PHF.	ТАМ			300	)			<u> </u>	,00		
D.L-Amphetamine	e sulf	ate	7	0			Dh	- MILE	~~~	1						
-Amphetamine			- ť					ente	rmine	Э			ŀ	300		
±) 3,4-Methylene			1	0,00	0		Ma	ente aproti	rmine	Э			1	300 2,50	0	
amphetamine	dioxv	,	1	0,00	0		Ma	ente aproti ethox	rmine line yphe	e nam	ine		1	300 2,50 2,000	0	
	edioxy	'	1	0,00 50	0		Ma Me D-	ente aproti ethox Ampl	rmine lline yphe hetar	e nam nine	ine			300 2,50 2,000 300	0	
	edioxy	'	1	0,00 50 <u>BA</u> F	0 RBIT	URA'	Ma Me D-	ente aproti ethox Ampl (BAF	rmine iline yphe hetar R 300	enam nine	ine			300 12,50 2,000 300	0	
Amobarbital	edioxy	1	1	0,00 50 <b>BAR</b> ,000	0 RBIT	URA'	Ma D- TES Alp	ente aproti ethox Ampl (BAF	rmine lline yphe hetar <b>R 300</b>	enam nine ))	ine			300 12,50 2,000 300	0	
Amobarbital 5,5-Diphenylhyda	edioxy	'	1 1 3 6	0,00 50 BAR ,000 ,000	0 RBITI	URA'	Ma D- TES Alp Ap	ente aproti ethox Ampl (BAF ohen oroba	rmine lline yphe hetar <b>R 300</b> ol rbital	enam mine ))	ine			300 12,50 2,000 300 300 450	0	
Amobarbital 5,5-Diphenylhyda Allobarbital	edioxy Intoin	1	1 1 3 6 4	50 50 BAF ,000 ,000 50	0 RBIT	URA'	Ma D- TES Alp Bu	aproti aproti Ampl (BAF oheno oroba itaba	rmine lline yphe hetar <b>R 300</b> ol rbital rbital	enam mine ))	ine			300 12,50 2,000 300 300 450 150	0	
Amobarbital 5,5-Diphenylhyda Allobarbital Barbital	edioxy	1	1 1 3 6 4 6	50 50 000 000 50 000	0 RBIT	URA'	Ma D- TES Alp Bu Bu	ente aproti ethox Ampl (BAF oheno oroba itaba itaba	rmine line yphe hetar <b>R 30(</b> ol rbital rbital	enam mine ))	ine			300 12,50 2,000 300 300 450 150 5,000	0	
Amobarbital 5,5-Diphenylhyda Allobarbital 3arbital Falbutal	ntoin	/	1 1 3 6 4 6 3	50 50 000 000 50 000 0		URA'	Ma D- TES Alp Bu Bu Bu	aproti ethox Ampl (BAF ohen oroba itaba itaba itaba	rmine lline yphe hetar <b>300</b> ol rbital rbital al	enam mine ))	ine			300 12,50 2,000 300 300 450 150 5,000 450	0	
Amobarbital 5,5-Diphenylhyda Allobarbital 3arbital Falbutal Cyclopentobarbita	edioxy Intoin	/	1 1 3 6 4 6 3 2	50 <b>BAF</b> ,000 ,000 50 ,000 0 5,000 0		URA'	Ma D- TES Alp Bu Bu Bu Bu	aproti aproti ethox Ampl (BAF oheno oroba itaba itaba itaba itaba	rmine line yphe hetar <b>300</b> ol rbital rbital al al oarbit	enam mine ))	ine			300 12,50 2,000 300 300 450 150 3,000 450 300	0	
Amobarbital 5,5-Diphenylhyda Allobarbital 3arbital Falbutal Cyclopentobarbita Pentobarbital	ntoin		1 3 6 4 6 3 2 6	50 50 ,000 ,000 50 ,000 5,000 5,000 5,000		URA	Ma D- TES Alp Bu Bu Bu Bu Se	ente aproti ethox Ampl (BAF ohen oroba itaba itaba itaba itaba itaba	rmine line yphe hetar <b>300</b> ol rbital rbital al barbita	enam mine ))	ine			300 12,50 2,000 300 300 450 150 3,000 450 300 300	0	
Amobarbital 5,5-Diphenylhyda Allobarbital Sarbital Falbutal Cyclopentobarbital Pentobarbital	ntoin		1 3 6 4 6 3 2 6	50 50 ,000 50 ,000 5,000 5,000 5,000 BAF		URA	Ma D- TES Alp Bu Bu Bu Bu Bu Bu Bu Bu	ente aproti ethox Ampl (BAF ohen oroba itaba itaba itaba itaba itaba itaba itaba itaba	rmine line yphe hetar <b>R 300</b> ol rbital rbital al oarbita rbital <b>R 200</b>	enam mine )) al	ine			300 12,50 2,000 300 300 150 150 300 300 300 300 300 300		
Amobarbital 5,5-Diphenylhyda Allobarbital Barbital Talbutal Cyclopentobarbital Pentobarbital Amobarbital	ntoin al		1 3 6 4 6 3 2 6 2	50 <b>BAR</b> ,000 ,000 50 ,000 5,000 <b>BAR</b> ,000 <b>BAR</b>		URA	Ma D- TES Alp Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu	Ample aproti ethox Ample (BAF ohen oroba itaba itaba itaba itaba itaba itaba itaba itaba itaba itaba itaba itaba itaba	rmine line yphe hetar <b>300</b> ol rbital rbital al oarbita rbital <b>a</b> <b>barbita</b> <b>c</b> <b>c</b> <b>c</b> <b>c</b> <b>c</b> <b>c</b> <b>c</b> <b>c</b> <b>c</b> <b>c</b>	enam mine )) al	ine			300 12,50 2,000 300 300 450 150 300 450 300 300 200 200		
Amobarbital 5,5-Diphenylhyda Allobarbital Barbital Cyclopentobarbital Pentobarbital Amobarbital 5,5-Diphenylhyda	ntoin		1 3 6 4 6 3 2 6 2 4 6	50 50 <b>BAF</b> ,000 ,000 50 ,000 5,000 <b>BAF</b> ,000 00 00		URA	Ma D- TES All Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu	Ample Ample Ample (BAF ohenoroba itaba	rmine line yphe hetar <b>300</b> ol rbital rbital al barbital rbital <b>200</b> ol rbital	enam mine )) al	ine			300 12,50 2,000 300 300 450 150 300 450 300 300 200 300 300		
Amobarbital 5,5-Diphenylhyda Allobarbital Barbital Falbutal Cyclopentobarbital Pentobarbital Amobarbital 5,5-Diphenylhyda Allobarbital Barbital	ntoin al		1 3 6 4 6 3 2 6 2 4 3 2 6	50 <b>BAF</b> ,000 ,000 50 ,000 5,000 <b>BAF</b> ,000 00 00 00		URA	Ma Ma D TES Alt App Bu Bu Bu Bu Bu Bu Bu Bu App App App App App Bu	aproti aproti athox Ampl (BAF ohen oroba itaba itaba itaba coba (BAF ohen oroba itaba	rmine lline yphe hetar <b>R 300</b> ol rbital al parbita <b>R 200</b> ol rbital rbital	e nam nine ))) cal I I	ine			300 2,50 2,000 300 300 300 50 50 50 50 50 300 30		
Amobarbital 5,5-Diphenylhyda Allobarbital Barbital albutal Cyclopentobarbital Pentobarbital 5,5-Diphenylhyda Allobarbital Barbital Calbutal	al al		1 33 66 4 6 33 22 6 6 7 2 4 3 3 4 4 3 3 4	50 50 ,000 ,000 50 ,000 5,000 ,000 ,000	0 8 <b>BIT</b> 0 8 <b>BIT</b>	URA URA	Ma Me D TES Alp Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu	ente aprotiti ethox Ampl (BAF (BAF oroba itaba itaba itaba itaba (BAF oroba (BAF oroba ita	rmine lline yphe hetar <b>R 300</b> ol rbital rbital al parbit rbital <b>R 200</b> ol rbital	e mamine mine aal	ine			300 2,500 2,000 300 450 50 50 50 50 50 50 50 50 50		
Amobarbital 5,5-Diphenylhyda Allobarbital Barbital falbutal Cyclopentobarbital Pentobarbital Amobarbital Amobarbital Amobarbital Barbital Barbital Sarbital Sarbital	al			0,000 50 50 50 50 5,000 5,000 5,000 6 5,000 6 6 6 6 6 6 6 6 7,000 0 0 7,000 0 0 7,000		URA	Ma Me D- TES Alp Bu Bu Bu Ph Se TES Alp Bu Bu Bu Bu Bu Bu	ente aproti tethox Amppi (BAF tethox taba taba taba taba taba taba taba tab	rmine line yphe hetar <b>R 300</b> ol rbital rbital al oarbit rbital rbital rbital rbital rbital al oarbit al	ee mammine ))) aal I )))	ine			300 2,500 2,000 300 450 150 300 150 300 300 300 150 300 150 300 150 300 150 300 150 300 150 300 150 150 150 150 150 150 150 1		
Amobarbital 5,5-Diphenylhyda Vilobarbital arbital albutal Cyclopentobarbital Pentobarbital Amobarbital Amobarbital Jobarbital arbital Parbital Pentobarbital	ntoin ntoin		1 3 6 4 6 3 3 2 6 6 3 3 2 6 6 4 4 2 2 4 4 2 1 1 1	0,000 50 50 ,000 50 ,000 5,000 5,000 0 5,000 0 0 0	0 8 <b>BIT</b> 0 8 <b>BIT</b>	URA URA	Ma Me D Alp Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu	ente aproti tethox Ampl (BAF tetho t	rmine line yphe hetar <b>R 300</b> ol rbital rbital al rbital <b>R 200</b> ol rbital rbital rbital rbital rbital rbital rbital	e mamine )) aal I )))	ine			300 12,50 2,000 300 300 50 50 50 50 50 300 30		
Amobarbital 5,5-Diphenylhyda Allobarbital aarbital Falbutal Cyclopentobarbital Pentobarbital i,5-Diphenylhyda Allobarbital aarbital albutal Cyclopentobarbital Pentobarbital	ntoin ntoin al		1 1 3 6 4 6 3 3 3 2 2 6 6 4 4 2 2 4 4 4 2 2 4 4 4 4 4 8 8 8 8 8 8	0,000 50 <b>BAF</b> ,000 ,000 50 ,000 0 5,000 0 <b>BAF</b> ,000 0 0 7,000 0 <b>ENZ</b>		URA	Ma Ma D Alp Ap Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu	ante aproti athox Amplo (BAR (BAR (BAR (BAR (BAR (BAR (BAR (BAR	rmine line yphe hetar rbital rbital al barbital rbital rbital rbital rbital al barbit rbital al barbit rbital rbital	enam mine )) ( aal ( )) ( aal ( ))	ine			300 12,50 2,000 300 300 50 50 50 50 300 450 300 450 300 450 300 450 300 450 300 450 300 450 300 450 300 450 450 450 450 450 450 450 4		
Amobarbital 5,5-Diphenylhyda Niobarbital Barbital Talbutal Cyclopentobarbital Cyclopentobarbital Amobarbital So-Diphenylhyda Miobarbital Barbital Talbutal Syclopentobarbital Pentobarbital	ntoin al		1 1 3 6 4 6 6 3 3 2 2 6 6 4 4 6 6 3 3 2 2 6 6 4 4 4 6 6 3 3 2 2 6 6 4 4 6 6 7 8 6 7 8 7 8 6 7 8 7 8 7 8 7 8 7 8	0,000 50 <b>BAR</b> ,000 ,000 50 ,000 0 5,000 0 5,000 0 <b>BAR</b> ,000 0 0 7,000 0 <b>ENZ</b> 00 0 0 0 0 0 0 0 0 0 0 0 0		URA URA	Ma Ma D- TES Alış Bu Bu Bu Bu Se TES Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu	ante aproti athox Amplo (BAR (BAR (BAR traba trab trab	rmine yphe hetar <b>3 30</b> ( ol rbital al barbital rbital <b>3 20</b> ( ol rbital al barbital al barbital al col rbital <b>3 20</b> ( ol rbital al col rbital al col rbital al col rbital al col rbital al col rbital col col col col rbital col col col col col col col co	enam mine )) aal I )) (aal I (aal I (aal I )) (aal Martine Martine (aal Martine Martine (aal Martine Martine Martine (aal Martine Martine (aal Martine Martine (aal Martine (aal Martine (aal Martine) (aal Martine (aal Martine)				300 2,50 2,000 300 50 50 50 50 50 50 50 50 50		
Amobarbital 5,5-Diphenylhyda Allobarbital Barbital albutal Cyclopentobarbital Pentobarbital Amobarbital Amobarbital Allobarbital Barbital Pentobarbital Pentobarbital Pentobarbital Pentobarbital Pentobarbital Pentobarbital	ntoin al ntoin	·	1 1 3 6 4 6 3 3 2 4 6 3 3 4 4 3 3 4 4 4 3 3 4 4 4 3 3 4 4 4 3 3 4 4 4 3 3 2 4 4 3 3 2 4 4 3 3 2 4 6 6 4 4 5 7 6 6 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7	0,000 50 <b>BAR</b> ,0000 ,0000 50 0 5,000 ,0000 0 0 0 0 0 0 0 0 0 0 0 0			Ma Ma D TES Alıt Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu	ente aproti tethox Ampl (BAF bhen roba ttaba ttaba ttabi ttetha ttetha ttetha ttetha ttetha ttetha secoba ttaba ttabi ttetha secoba ttaba ttaba ttaba ttaba ttetha secoba	rmine yphe hetar <b>300</b> ol rbital rbital al arbital rbital rbital rbital rbital rbital rbital <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b> <b>300</b>	e nam nine )) ( aal ( )) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) (	e			300 2,500 2,000 300 50 50 50 50 50 50 50 50 50		
Amobarbital 5,5-Diphenylhyda Allobarbital Barbital Cyclopentobarbital Pentobarbital Amobarbital Amobarbital Allobarbital Falbutal Cyclopentobarbital Pentobarbital Pentobarbital Iprazolam -hydroxyalprazo Jobazam	ntoin al al		1 1 3 6 6 6 4 4 6 6 7 2 2 6 6 7 2 6 6 7 2 2 6 6 7 2 7 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	0,000 50 <b>BAR</b> ,0000 50 0 5,000 0 <b>BAR</b> ,0000 0 0 0 0 0 0 0 0 0 0 0 0	0 8BIT 0 8BIT 0 0 0 0 0	URA URA	Ma Ma D TES Alp Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu	ente aproti tethox Ampl (BAF bhen rroba ttaba tt	rmine line yphe hetar al ol rbital al arbital rbital rbital rbital al arbital rbital al arbital rbital col rbital rbital al arbital rbital al arbita	e nam nine )) cal l l l l l l n oxide	e e			300 2,500 300 300 550 550 550 550 550		
Amobarbital 5,5-Diphenylhyda Allobarbital aarbital Talbutal 2yclopentobarbital 2yclopentobarbital 3,5-Diphenylhyda Allobarbital 3arbital 3arbital 2yclopentobarbital 2yclopentobarbital 4yprazolam 1-hydroxyalprazo Jobazam 2lonazepam	ntoin al ntoin al al		1 1 3 66 4 4 6 3 2 2 6 4 4 3 3 4 4 4 2 2 2 4 4 4 2 2 3 3 6 6 6 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	0,000 50 <b>BAR</b> ,000 ,000 50 ,000 0 <b>BAR</b> ,000 0 <b>BAR</b> ,000 0 0 0 0 0 0 0 0 0 0 0 0	0 8BIT 0 8BIT 0 0 0 0 0 0	URA URA	Ma Ma D TES Alp Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu	eente aproti dente Ampl (BAF Johen proba attaba attabi tittetha attabi attabi	rmine line yphe hetar hetar al orbital rbital rbital al oarbit rbital <b>200</b> ol rbital <b>200</b> ol rbital al oarbit rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b>	e nam mine )) cal l l l l l l l l l l l l l l l l l l	ine			300 2,500 300 300 550 550 550 550 550		
Amobarbital 5,5-Diphenylhyda Allobarbital Barbital Talbutal 2yclopentobarbital 2yclopentobarbital Amobarbital 3arbital 3arbital 2yclopentobarbital 2yclopentobarbital 1yprazolam 1-hydroxyalprazo 2lonazepam 2lonazepate dipol	Intoin al al al al al		1 1 3 3 4 4 6 6 3 3 2 2 2 4 4 3 3 4 4 4 4 4 4 4 4 4 2 2 1 1 1 1 1 1 1 1 1	0,000 50 <b>BAR</b> ,000 0,000 5,000 0 <b>BAR</b> ,000 0 <b>BAR</b> ,000 0 0 0 0 0 0 0 0 0 0 0 0		URA URA	Maa Maa D TES Alp Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu Bu	ente aproti tethox Ampl (BAF obhen proba ttaba ttabi ttetha enob coba ttaba ttabi ttetha ttaba ttabi ttetha ttaba ttabi ttetha ttab	rmine line yphe hetar hetar al orbital rbital al oarbit rbital al oarbit rbital al oarbit rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital al oarbit rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> ol rbital <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>200</b> <b>20</b> <b>2</b>	e nam mine )) aal l aal l J)) m oxide zepo m	ine 			300 12,50 2,000 300 150 150 150 300 150 300 150 300 150 300 150 300 150 300 150 150 150 150 150 150 150 1		

Desalkylflurazenam	300	Temazenam	200
Elunitrazenam	300	Diazenam	2 500
(+) Lorazepam	5.000	Estazolam	10.500
RS-Lorazepam glucuronide	300	Triazolam	5,000
Midazolam	10,500		
	BENZODIAZEPII	NES (BZO 300)	
Alprazolam	100	Bromazepam	780
a-hydroxyalprazolam	1,500	Chlordiazepoxide	780
Clobazam	200	Nitrazepam	200
Clonazepam	390	Norchlordiazepoxide	100
Clorazepate dipotassium	390	Nordiazepam	780
Delorazepam	780	Oxazepam	300
Desalkylflurazepam	200	Temazepam	100
Flunitrazepam	200	Diazepam	1,500
(±) Lorazepam	3,100	Estazolam	6,250
RS-Lorazepam glucuronide	200	Triazolam	3,100
Midazolam	6,250		
	BENZODIAZEPI	NES (BZO 200)	
Alprazolam	70	Bromazepam	520
a-hydroxyalprazolam	1,000	Chlordiazepoxide	520
Clobazam	120	Nitrazepam	120
Clonazepam	260	Norchlordiazepoxide	70
Clorazepate dipotassium	260	Nordiazepam	520
Delorazepam	520	Oxazepam	200
Desalkylflurazepam	120	Temazepam	70
Flunitrazepam	120	Diazepam	1,000
(±) Lorazepam	2,000	Estazolam	4,200
RS-Lorazepam glucuronide	120	Triazolam	2,000
Midazolam	4,200		
	BENZODIAZEPI	NES (BZO 100)	
Alprazolam	40	Bromazepam	260
a-hydroxyalprazolam	500	Chlordiazepoxide	260
Clobazam	60	Nitrazepam	60
Clonazepam	130	Norchlordiazepoxide	40
Clorazepate dipotassium	130	Nordiazepam	260
Delorazepam	260	Oxazepam	100
Desalkylflurazepam	60	Temazepam	40
Flunitrazepam	60	Diazepam	500
(±) Lorazepam	1.000	Estazolam	2,100
RS-Lorazepam glucuronide	60	Triazolam	1.000
Midazolam	2,100		1
	BUPRENORP	HINE (BUP)	1
Buprenorphine	10	Norbuprenorphine	50
Buprenorphine	50	Norbuprenorphine	100
3-D-Glucuronide		3-D-Glucuronide	
	COCAINE (	COC 300)	
Benzoylecgonine	300	Cocaethylene	12,500
Cocaine HCl	200	Ecgonine	30,000
	COCAINE (	COC 150)	
Benzoylecgonine	150	Cocaethylene	6,250
Cocaine HCI	100	Ecaonine	15.000
	COCAINE (	COC 100)	
Benzovlecgonine	100	Cocaethylene	5,000
Cocaine HCI	80	Ecoonine	10.000
	MARIJUANA	(THC150)	,
Cannabinol	50.000	À8-THC	45.000
11-nor-△8-THC-9 COOH	90	△9-THC	45.000
11-nor-△9-THC-9 COOH	150		
	MARIJUAN	A (THC50)	•
Cannabinol	20.000	∆8-THC	15.000
11-nor-△8-THC-9 COOH	30	∆9-THC	15,000
11-nor-△9-THC-9 COOH	50	-	,
		(THC 25)	
Cannabinol	MARIJUAN	4 (1110ZJ)	
	10,000	∆8-THC	7,500
11-nor-△8-THC-9 COOH	MARIJUAN 10,000 15	△8-THC △9-THC	7,500 7,500
11-nor-△8-THC-9 COOH 11-nor-△9-THC-9 COOH	MARIJUAN 10,000 15 25	△8-THC △9-THC	7,500 7,500
11-nor-∆8-THC-9 COOH 11-nor-∆9-THC-9 COOH	MARIJUAN 10,000 15 25 MARIJUAN	△8-THC △9-THC ↓ - THC ↓ - THC ↓ - THC20)	7,500 7,500
11-nor-△8-THC-9 COOH 11-nor-△9-THC-9 COOH Cannabinol	MARIJUAN 10,000 15 25 MARIJUAN 10,000	△8-THC △9-THC ▲9-THC <b>4 (THC20)</b> △8-THC	7,500 7,500 7,500
11-nor-△8-THC-9 COOH 11-nor-△9-THC-9 COOH Cannabinol 11-nor-△8-THC-9 COOH	MARIJUAN 10,000 15 25 MARIJUAN 10,000 15	A8-THC △9-THC △9-THC A (THC20) △8-THC △9-THC	7,500 7,500 7,500 7,500 7,500
11-nor-∆8-THC-9 COOH 11-nor-∆9-THC-9 COOH Cannabinol 11-nor-∆8-THC-9 COOH 11-nor-∆9-THC-9 COOH	MARIJUAN 10,000 15 25 MARIJUAN 10,000 15 20	AB-THC △9-THC ▲9-THC <b>4 (THC20)</b> △8-THC △9-THC	7,500 7,500 7,500 7,500 7,500
11-nor-∆8-THC-9 COOH 11-nor-∆9-THC-9 COOH Cannabinol 11-nor-∆8-THC-9 COOH 11-nor-∆9-THC-9 COOH	MARIJUAN 10,000 15 25 MARIJUAN 10,000 15 20 METHADONI	A(THC20) A9-THC A(THC20) A8-THC A9-THC A9-THC E(MTD300)	7,500 7,500 7,500 7,500 7,500
11-nor-△8-THC-9 COOH 11-nor-△9-THC-9 COOH Cannabinol 11-nor-△8-THC-9 COOH 11-nor-△9-THC-9 COOH Methadone	MARIJUAN 10,000 15 25 MARIJUAN 10,000 15 20 METHADONI 300	A(THC20) A(THC20) A(THC20) A:THC	7,500 7,500 7,500 7,500 7,500 100,000
11-nor-∆8-THC-9 COOH 11-nor-∆9-THC-9 COOH Cannabinol 11-nor-∆8-THC-9 COOH 11-nor-∆9-THC-9 COOH 11-nor-∆9-THC-9 COOH Methadone	MARIJUAN 10,000 15 25 MARIJUAN 10,000 15 20 METHADONI 300 METHADONI	A(THC23) A8-THC A9-THC A(THC20) A8-THC A9-THC CMTD300) Doxylamine E(MTD300)	7,500 7,500 7,500 7,500 7,500 100,000
11-nor-∆8-THC-9 COOH 11-nor-∆9-THC-9 COOH Cannabinol 11-nor-∆8-THC-9 COOH 11-nor-∆9-THC-9 COOH Methadone Methadone	MARIJUAN 10,000 15 25 MARIJUAN 10,000 15 20 METHADONI 300 METHADONI 200	A (THC20) A 9-THC A (THC20) A (THC20) A 8-THC A 9-THC (MTD300) Doxylamine E (MTD200) Doxylamine Doxylamine	7,500 7,500 7,500 7,500 7,500 100,000 60,000
11-nor-△8-THC-9 COOH 11-nor-△9-THC-9 COOH Cannabinol 11-nor-△8-THC-9 COOH 11-nor-△9-THC-9 COOH Methadone Methadone	MARIJUAN 10,000 15 25 MARIJUAN 10,000 15 20 METHADONI 300 METHADONI 200 METHADONI	A(THC20) A8-THC A(THC20) A8-THC A9-THC E(MTD300) Doxylamine E(MTD200) Doxylamine Doxylamine INE (MET1, 000)	7,500 7,500 7,500 7,500 7,500 100,000 60,000
11-nor-△8-THC-9 COOH           11-nor-△9-THC-9 COOH           Cannabinol           11-nor-△8-THC-9 COOH           11-nor-△9-THC-9 COOH           Methadone           Methadone           Methadone           Methadone	MARIJUAN. 10,000 15 25 MARIJUAN. 10,000 15 20 METHADONI 300 METHADONI 200 METHADONI 200 15 200 15 200 15 200 15 200 15 200 15 20 15 15 15 15 15 15 15 15 15 15	A (THC20) AB-THC A (THC20) AB-THC AB-THC CMTD300) Doxylamine C(MTD200) Doxylamine INE (MET1, 000) (+)-3.4-Methylenedioxy-	7,500 7,500 7,500 7,500 100,000 60,000 6,250
11-nor-∆8-THC-9 COOH 11-nor-∆9-THC-9 COOH Cannabinol 11-nor-∆8-THC-9 COOH 11-nor-∆9-THC-9 COOH Methadone Methadone Methadone P-Hydroxymethamphetamine	MARIJUAN. 10,000 15 25 MARIJUAN. 10,000 15 20 METHADONI 200 METHADONI 200 METHADONI 200 15 10,000 10,0	A(THC23) △8-THC △9-THC △9-THC △9-THC E(MTD300) Doxylamine E(MTD200) Doxylamine INE (MET1,000) (±)-3,4-Methylenedioxy- methamphetamine	7,500 7,500 7,500 7,500 100,000 80,000 6,250
11-nor-△8-THC-9 COOH           11-nor-△9-THC-9 COOH           Cannabinol           11-nor-△8-THC-9 COOH           11-nor-△9-THC-9 COOH           Methadone           Methadone           P-Hydroxymethamphetamine           P-Methamphetamine	MARIJUAN/ 10,000 15 25 MARIJUAN/ 10,000 15 20 METHADONI 200 METHADONI 200 METHADONI 200 METHADONI 200 1000 1,000 1,000	A (THC20) A (THC20) A (THC20) A (THC20) A (THC20) A (THC20) Doxylamine E (MTD300) Doxylamine E (MTD200) Doxylamine INE (MET1, 000) (±)-3,4-Methylenedioxy- methamphetamine Mephentermine	7,500 7,500 7,500 7,500 7,500 100,000 60,000 6,250 50,000
11-nor-∆8-THC-9 COOH 11-nor-∆9-THC-9 COOH Cannabinol 11-nor-∆8-THC-9 COOH 11-nor-∆9-THC-9 COOH Methadone Methadone Methadone C-Hydroxymethamphetamine D-Methamphetamine L-Methamphetamine	MARIJUAN. 10,000 15 25 MARIJUAN. 10,000 15 20 METHADONI 200 METHADONI 200 10,000 12,500 METHAMPHETAN 25,000 12,500	A (THC23) AB-THC A (THC20) AB-THC AB-THC CMTD300) Doxylamine (MTD300) Doxylamine (MT200) Doxylamine INE (MET1, 000) (±)-3.4-Methylenedioxy- methamphetamine Mephentermine MINE (MET500)	7,500 7,500 7,500 7,500 100,000 60,000 6,250 50,000

o-Hydroxymethamphetamine	12 500	(+)-3 4-Methylenedioxy-	3 000
D-Methamphetamine	500	methamphetamine	0,000
	0.000	Monhontormino	25.000
			23,000
			4 000
p-Hydroxymethamphetamine	7,500	(±)-3,4-Methylenedloxy-	1,800
D-Methamphetamine	300	methamphetamine	
L-Methamphetamine	3,750	Mephentermine	15,000
METHYLENEDIO	XYMETHAMPHE	TAMINE (MDMA1, 000) Ecst	asy
(±) 3,4-Methylenedioxymethan	nphetamine HCI		1,000
3,4-Methylenedioxyethyl-amph	netamine		600
(±) 3.4-Methylenedioxyamphet	amine HCI		6.000
METHYLENEDI	OXYMETHAMPH	FTAMINE (MDMA500) Ecsta	sv
(+) 3 4-Methylenedioxymethan	nhetamine HCI		500
3 4-Methylenedioxyethyl-ampt			300
(+) 3 4 Mothylonodioxyamphot			3 000
		ETAMINE (MDMA250) Eag	5,000
		ETAMINE (MDMA250) ECS	lasy
(±) 3,4-Ivietnylenedloxymethan	nphetamine HCI		250
3,4-Methylenedioxyethyl-ampr	netamine		150
(±) 3,4-Methylenedioxyamphet	amine HCI		1,500
METHYLENEDIO	XYMETHAMPH	ETAMINE (MDMA300) Ecs	tasy
(±) 3.4-Methylenedioxymethan	nphetamine HCI		300
3.4-Methylenedioxyethyl-amph	etamine		180
(+) 3 4-Methylenedioxyamphet	amine HCI		1 800
	MORPHINE	(MOP 300)	1,000
Codoino	200	Norcodoino	6 000
Lovernhanel	1 500	Normarphona	5,000
Levolphanol Membine 2.6 D. Chuguranide	1,300		30,000
Ethylmorphine	6000 6.000	Oxycodolle	50,000
	0,000	Disardia	
Hydrocodone	000,000	Procaine	15,000
Hydromorphone	3,000	Ihebaine	6,000
6-Monoacethylmorphine	400	Morphine	300
	MORPHINE	(MOP 100)	
Codeine	80	Norcodeine	2,000
Levorphanol	500	Normorphone	20,000
Morphine-3-β-D-Glucuronide	300	Oxycodone	10,000
Ethylmorphine	2,000	Oxymorphone	20,000
Hydrocodone	20,000	Procaine	5,000
Hydromorphone	1,000	Thebaine	2,000
6-Monoacethylmorphine	100	Morphine	100
	Methagualone	e (MQL 300)	
Methagualone	300		
	MORPHINE/OPIA	TE (OPI 2,000)	
Codeine	2 000	Morphine	2 000
Ethylmorphine	3,000	Norcodeine	25.000
Hydrocodono	5,000	Normorphono	50,000
Hydrocodolie	12 500	Oxycodono	25,000
	12,300	Oxycodone	25,000
	25,000		25,000
6-ivionoacetyimorphine	3,000	Procaine	50,000
Morphine 3-β-D-glucuronide	2,000	Thebaine	25,000
-	MORPHINE/OPIA	ATE (OPI 1,000)	
Codeine	1000	Morphine	1000
Ethylmorphine	1,500	Norcodeine	12,500
Hydrocodone	25,000	Normorphone	25,000
Hydromorphone	6,250	Oxycodone	12,500
Levorphanol	12,500	Oxymorphone	12,500
6-Monoacetylmorphine	1,500	Procaine	25,000
Morphine 3-B-D-alucuronide	1.000	Thebaine	12.500
	PHENCYCI II	DINE (PCP)	
Phencyclidine	25	4-Hydroxyphencyclidine	6.250
	PROPOXYPH	IENE (PPX)	
D-Propoxyphene	300	D-Norpropoxyphene	300
три		PRESSANTS (TCA)	
Nortriptyline			400
Nordovopino	400	Clominramino	50,000
Triminromino	+00 2 000	Devenine	1 500
	0,000	Manaatilina	1,300
	1,300	iviaprotiline	1,000
Promazine	3,000	Promethazine	25,000
	200	Perphenazine	25,000
Cyclobenzaprine	1,500	l	
	Tramado	I (TRA)	
n-Desmethyl-cis-tramadol	200	o-Desmethyl-cis-tramadol	7,000
Cis-tramadol	100	Phencyclidine	100,000
Procyclidine	100,000	d,I-O-Desmethyl venlafaxine	50,000
	KETAMINE (	KET1, 000)	
Ketamine	1,000		
	KETAMINE	(KET500)	
Ketamine	500	-	
	KETAMINE	(KET300)	

	Oxycodor	ne (OXY)	
Oxvcodone	100	Hydromorphone	50.000
Oxymorphone	200	Naloxone	25,000
Levorphanol	50,000	Naltrexone	25,000
Hydrocodone	6 250	lanonono	20,000
nyarooodone	Cotinine ((	COT 200)	
() Cotining		() Nigoting	2 000
(-)-Countrie	200 Catinina ((		3,000
	Cotinine (C		4 500
(-)-Cotinine		(-)-INICOTINE	1,500
2-Ethylidene-1,	5-dimethyl-3,3-d	iphenylpyrrolidine (EDDP30	0)
2-Ethylidene-1,5-dimethyl-3,3-0	diphenylpyrrolidin	e (EDDP)	300
2-Ethylidene-1,	5-dimethyl-3,3-d	iphenylpyrrolidine (EDDP10	)0)
2-Ethylidene-1,5-dimethyl-3,3-0	diphenylpyrrolidin	e (EDDP)	100
	Fentanyl	(FYL20)	
Alfentanyl	600,000	Perphenazine	5,000
Fenfluramine	40,000	Fentanyl	100
Norfentanyl	20	Sufentanyl	60,000
Pipamperon	25,000	Risperdal	10,000
• •	Fentanvl	(FYL10)	
Alfentanyl	300.000	Perphenazine	2.500
Fenfluramine	20,000	Fentanyl	50
Norfentanyl	10	Sufentanyl	30,000
Pipamperon	12.500	Risperdal	5.000
	Synthetic Marii	iuana (K2-50)	0,000
IWH-018 5-Pentanoic acid metab			50
WH-073 4-butanoic acid metabo	lite		50
WH-018 4-Hydroxypentyl metab	olite		400
WH-018 5-Hydroxypentyl metab	olite		600
WH-073 4-Hydroxybutyl metabol	lite		300
WH-018 N-Propagoic acid	inte		30
IWH-019 6-Hydroxybexyl			1 000
WH-122 N-4-Hydroxy/pentyl			1,000
PCS4 N-5-Carboxypentyl			45,000
MAM2201 N-Pentanoic acid			65
WH-210 N-5-Carboxyoentyl			400
IW/H-398 N-Pentanoic acid			350
IWH-200 6-Hydroxyindole			600
IWH-073 N-2-Hydroxybutyl			1 000
IWH-019 5-Hydroxybexyl			1,000
IWH-018			7,000
AM2201 N=(4-bydroxypentyl)			700
JWH-073 N-(3-bydroxybutyl)			450
	Synthetic Marii	iuana (K2-30)	100
IW/H-018 5-Pentanoic acid metab	olite	ualla (112-50)	80
WH-073 4-butanoic acid metabo	lito		30
WH-018 4-Hydroxypentyl metab	olite		250
WH-018 5-Hydroxypentyl metab	olite		250
WH 072 4 Hydroxybutyl metabo	lito		190
WH-018 N-Propanoic acid	inte		18
IW/H-019 6-Hydroxybexyl			600
IWH-122 N-4-Hydroxynexyl			600
PCS4 N-5-Carboxypentyl			27000
MAM2201 N-Pentanoic acid			27000
W/H-210 N-5-Carboxynentyl			240
IW/H-398 N-Pentanoic acid			240
IWH-200 6-Hydroxyindole			360
IWH-073 N-2-Hydroxybutyl			600
IWH-019 5-Hydroxybexyl			600
IWH-018			4200
AM2201 N-(4-bydroxypentyl)			4200
IW/H-073 N-(3-bydroxybutyl)			270
	Ethyl alucuroni	ido (ETG 500)	210
Ethyl gluguropido			500
Ethyl gluculonide	K2./AD D		500
	NZ+(AD-P	INACA)	10
AB-PINACA pentanoic acid me	etabolite		10
AB-PINACA N-(4-hydroxypenty	yl) metabolite		10
ADB-PINACA N-(4-hydroxyper	ntyl) metabolite		15
ADB-PINACA N-(5-hydroxyper	ntyl) metabolite		20
5-fluoro AB-PINACA N-(4-hydr	oxypentyl)		20
ADB-PINACA pentanoic acid n	netabolite		20
AB-PINACA N-(5-hvdroxvpenty	l) metabolite		30
5-fluoro AB-PINACA			50
AB-PINACA			100
AB-FUBINACA			150
			250
			1000
			>10.000
	exected as a first Pro-		/10,000
APINACA (AKB-48) 5-hydroxy	pentyl metabolite		>10,000
CUMYL-THPINACA			>100,000
5-fluoro AEB			>100,000
AB-CHMINACA metabolite M2			>100,000
PX 1 (5-fluoro APP-PICA)			>100.000

PX 2 (5-fluoro APP-PINACA)			>100,000				
5-fluoro ADB (5-fluoro MDMB	-PINACA)		>100,000				
4-cyano CUMYL-BUTINACA			>100,000				
MMB-FUBINACA			>100,000				
CUMYL-PICA			>100,000				
5-fluoro MN-18			>100,000				
MN-18 >100,000							
5-fluoro PB-22 3-carboxyindo	le metabolite		>100,000				
BB-22 3-carboxyindole metabolite >100,000							
AM 2201 N-(4-hydroxypentyl) metabolite >100,000							
Zolpidem (ZOL50)							
Zolpidem Phenyl-4-carboxylic	acid		50				
	Methcath	inone (MCAT)					
Methcathinone	1,000	Mephedrone	200				
MDPV	>100,000	Cathinone	>100,000				
	Mepheo	drone (MEP)					
Mephedrone	500	Methcathinone	5,000				
MDPV	>100,000	Cathinone	>100,000				
	UR-144	(UR-144 -25)					
UR144 5-Pentanoic acid meta	abolite		25				
UR144 5-Hydroxypentyl meta	bolite		1,000				

#### Effect of Urinary Specific Gravity

Fifteen (15) urine samples of normal, high, and low specific gravity ranges (1.000-1.037) were spiked with drugs at 50% below and 50% above cut-off levels respectively. The Multi-Drug Rapid Test Panel was tested in duplicate using fifteen drug-free urine and spiked urine samples. The results demonstrate that varying ranges of urinary specific gravity do not affect the test results.

#### Effect of Urinary Ph

The pH of an aliquoted negative urine pool was adjusted to a pH range of 5 to 9 in 1 pH unit increments and spiked with drugs at 50% below and 50% above cut-off levels. The spiked, pH-adjusted urine was tested with the Multi-Drug Rapid Test Panel. The results demonstrate that varying ranges of pH do not interfere with the performance of the test.

# Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds in either drug-free urine or drug positive urine containing, Amphetamine, Barbiturates, Benzodiazepines, Buprenorphine, Cocaine, Marijuana, Methadone, Methamphetamine, Methylenedioxymethamphetamine, Morphine, Tramadol, Ketamine, Phencyclidine, Propoxyphene, Tricyclic Antidepressants, Oxycodone, Cotinine, EDDP, Fentanyl, Synthetic, Marijuana, Ethyl Glucuronide, K2+, Zolpidem, Methcathinone, Mephedrone and UR-144. The following compounds show no cross-reactivity when tested with the Multi-Drug Rapid Test Panel at a concentration of 100µ/mL.

	Non Cross-Read	cting Compounds	
Acetophenetidin	Dextromethorphan	3-Hydroxytyramine	Quinidine
Acetylsalicylic acid	Diclofenac	Isoxsuprine	Quinine
Aminopyrine	Diflunisal	Ketoprofen	Salicylic acid
Ampicillin	Digoxin	Labetalol	Serotonin
Apomorphine	Diphenhydramine	Loperamide	Sulfamethazine
Aspartame	Ethyl-p-aminobenzoat	Nalidixic acid	Sulindac
Atropine	β-Estradiol	Norethindrone	Tetracycline
Benzilic acid	Estrone-3-sulfate	Noscapine	Tetrahydrozoline
Benzoic acid	Erythromycin	d,I-Octopamine	Thiamine
Bilirubin	Furosemide	Oxalic acid	Thioridazine
Chloramphenicol	Gentisic acid	Oxolinic acid	Tolbutamide
Chlorpromazine	Hemoglobin	Oxymetazoline	Triamterene
Cholesterol	Hydralazine	Penicillin-G	Trimethoprim
Cortisone	Hydrochlorothiazide	Perphenazine	d,I-Tryptophan
Creatinine	Hydrocortisone	Phenelzine	Uric acid
Deoxycorticosterone	o-Hydroxyhippuric acid	Prednisone	Verapamil
[BIBLIOGRAPHY]			

- Hawks RL, CN Chiang. Urine Testing for Drugs of Abuse. National Institute for Drug Abuse (NIDA), Research Monograph 73, 1986.
- 2. Tietz NW. Textbook of Clinical Chemistry. W.B. Saunders Company. 1986; 1735.
- Stewart DJ, Inaba T, Lucassen M, Kalow W. Clin. Pharmacol. Ther. April 1979; 25 ed: 464, 264-8.
- 4. Ambre J. J. Anal. Toxicol. 1985; 9:241.
- Winger, Gail, A Handbook of Drug and Alcohol Abuse, Third Edition, Oxford Press, 1992, page 146.
- 6. Robert DeCresce. Drug Testing in the workplace, 1989 page 114.
- Glass, IB. The International Handbook of Addiction Behavior. Routledge Publishing, New York, NY. 1991; 216
- B. Cody, J.T., "Specimen Adulteration in drug urinalysis. Forensic Sci. Rev., 1990, 2:63.
- 9. C. Tsai, S.C. et.al., J. Anal. Toxicol. 1998; 22 (6): 474
- Basel RC. <u>Disposition of Toxic Drugs and Chemicals in Man</u>. 6th Ed. Biomedical Publ., Foster City, CA 2002.
- 11. Hardman JG, Limbird LE. Goodman and Gilman's: The Pharmacological Basis for Therapeutics. 10th Edition. McGraw Hill Medical Publishing, 2001; 208-209.
- J.H. Lewis and J.H. Vine. "A Simple and Rapid Method for the Identification of Zolpidem Carboxylic Acid in Urine." Journal of Analytical Toxicology, Vol. 31, May 2007.
- SALVAP,COSTAJ. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications[ J]. ClinPharmacokinet, 1995, 29(3): 142 -153.

	Index of Symbols												
Ĩ	Consult Instruction for use		$\sum_{i=1}^{n}$	Tests per kit		EC REP	Authorized Representative						
IVD	For <i>in vitro</i> diagnostic use only			Use by		$(\mathbf{X})$	Do not reuse						
c 30°C	Store between 2-30°C		LOT	Lot Number		REF	Catalog #						
8	Do not use if package is damaged												



EC REP Shanghai International Holding Corp. GmbH (Europe) Elffestrasse 80, 20537 Hamburg, Germany

Number: RP5039521 Effective date: 2021-11-05